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1. INTRODUCTION 
 
jäœ k©lyikªJª jhéa Phd« 
cäœtJ nghy cyfª Âçth® 
méGkdK bk«khÂ a¿Î¤ 
jäœ k©ly ikªJ¤ j¤Jthnk.  
                                                                                     - ÂUkªÂu«             
Health is a state of complete harmony of the body, mind and spirit when one is 
free from physical disabilities and mental distractions, the gates of the soul open. The 
saying “Health is Wealth” signifies the importance of health.  
According to the “World Health Organisation”, the main determinants of the 
health include the social and economic environment, the physical environment and 
personal individual characteristics and behaviours. It is also reported that environment 
degradation coupled with the growth in world population are major causes behind the 
rapid increase in human diseases with increase is health standards there is an increase in 
life expectancy of the general  public all over the world.  
This can be achieved by integrating all systems of medicine .  
          Siddha system is an ancient system of medicine developed with the civilization of 
Harappa and Mohanjatharo of the Indus river valley about 6000 -7000 years ago. It can be 
considered as the crown of the traditional arts of the ancient world owing to its richness 
and simplicity. Prevention and cure of illness is the basic aims of all systems of medicine. 
The Siddha system is addition a transcendental motivation a concern for what might be 
called the “Immortality of the Body”. More over the system not only deals with medicine 
but also with spiritually, the righteous way of living and rejunuvation.  
   In Siddha system of medicine balavagadam is one among the branch which is 
especially dealing with the diseases mainly in the pediatric population. Some other books 
such as Vaalai Vagadam, Agasthiar Vaithiya Pillai Thamizh, Thirumoolar Karukadai 
Vagadam 600, Thanuvin Sangira Sinthamani also explains about diseases of children.  18 
siddhars are the rulers of the sidddha system in this system one among the saint 
Thirumoolar quotes, 
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  “Â§fŸ g¤jh»š njÍnthL thÍnr®ªJ 
   m§»ky®¤Â mkëah Ñœneh¡» 
   bgh§» ÃwªjehŸ òfœth® btWÅz® 
   j§»¢ brå¡ifæš jh‹nehÍ« c‰wnj” 
                                   -   ÂU_y® fU¡fil it¤Âa« 600 
The dearangement of three humours initiates the child’s birth process since this 
kind of dearangement is explained as the disease.  
According to WHO child health is a state of physical, mental intellectual, social 
and emotional well being and not merely the absence of disease or infirmity. Healthy 
Children live in families, environments and communities that provide them with the 
opportunity to reach their fullest developmental potential.  
Children cannot achieve optimal health alone. Maternal health status, habits and 
environment during and even before pregnancy profoundly impact the health and 
wellbeing of the child. Since the child health is foundational to adult health. The common 
peadiatric disease named “kanam” has the same disease pathology. It has been classified 
into 24 types in Siddha system. Neerkanamantham is one among them. It affects the 
respiratory tract causing cough, rhinorrhoea, intermittent fever and general myalgia in 
children.  
Respiratory diseases are a major cause of morbidity and mortality in developing 
countries. Upper respiratory tract infections comprised 87. 5% of total acute respiratory 
infections morbidity. Data suggest that children could suffer from 7 to 8 episodes of 
upper respiratory tract infections per year until they are 5 years of age, when their 
immune status reaches adult level. upper respiratory tract infections(URI) represents the 
most common acute illness evaluated in out patient. Acute upper respiratory tract 
infections (URTIs) are common diseases in young children and contributes to 
approximately 20% of mortality in children younger than 5 years of age.  
The common cold Is One Among the  upper respiratory tract infections(URI) is 
highly prevalent incidence among young children and 61% resuls in Otitis media(OM) 
18% of children whom consumed antihistamines containing combination of preparion had 
contraindication. (jhaj R et al 2001) also plays significant role of complications such as 
exacerbations of asthma.  
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Athimathura chooranam a herbal formulation mentioned in sastric siddha 
literature, Balavagadam and it is indicated for all types of kanam. The chief drug of 
experimental formulation Athimathuram(Glycyrhyza glabra) having anti inflammatory 
activity( wang CY et al 2011) ,Lavangapattai (Cinnamomum verum)  having anti allergic 
activity (Shin YW et al 2007). Korai(Cyperus rotundus) having antipyretic activity(Gupta 
MB et al 1971) and all drugs having anti inflammatory activity.   
This drug is commonly used in clinical practice. Since the formulation has not 
undergone any  clinical trial hence the authour has selected Athimathura chooranam in 
the treatment of Neerkanamantham. So this siddha formulations efficacy has to be 
evaluated scientifically and documented.  
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2. AIM AND OBJECTIVES 
AIM  
To evaluate the efficacy of ATHIMATHURA CHOORANAM for the 
management of  (Common cold) 
OBJECTIVES  
1. To collect and review the ideas mentioned in the ancient Siddha literature 
about the disease  
2. To explore definition, etiology, clinical features, diagnosis, investigations and 
treatment of valikanam as laid down from various siddha literature 
Neerkanamantham.  
3. To study the disease Neerkanamantham on the basis of three thodam, 
envagaithervugal, neerkuri, neikuri, udal thathukkal, paruvakaalangal, age, sex 
and economic status.  
4. To make the correlative study of the siddha and modern aspect of this disease.  
5. To use the modern parameters in the investigation of the disease that enhances 
to observe the progess of the patient.  
6. To conduct a clinical study to find out the efficacy of ATHIMATHURA  
CHOORANAM  
7. To have a detailed analysis of the disease Neerkanamantham through the 
clinical efficacy of the drugs.  
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3. REVIEW OF LITERATURE 
 
3. 1 SIDDHA ASPECT 
 
ePHf;fzkhe;jk; 
fzk ; - ,ay;(Definition) :       
khjhf;fspd; gpjhf;fspd; ehj tpe;Jf;fslq;fpa thjhjp Njh\q;fspdpd;W 
cw;gj;jpahfpf; fUg;ghraj;J rpRitg; gw;wp mr;rpRthdJ VOtif jhJf;fSk; 
td;ikailAq;fhyj;J mij tUe;j nra;Ak; Neha;. 
I fz Nuhfk;; : 
Foe;ijfSf;F fzr;#l;bdhYk; ghypd; Fw;wj;jpdhYk; tapW 
Nfhshwile;J clk;gpy; fdg;Gz;lhfpr; Ruk; tpau;it euk;G typ Kjypad 
Vw;gl;L vYk;G FWfp clk;G ,isj;J tUk; Neha;.  
    rpj;j kUj;Jt E}yhd ghythflk; (Foe;ij kUj;Jtk;);> fzj;jpid %d;W 
tifapy; tiuKiwg;gLj;Jfpd;wJ. mit tUk; topapidg; nghWj;J ,U 
gphpTfSk;> Njhd;Wk; tajpidg; nghWj;J xU gphpTk; MFk;. 
II.fzk; Njhd;Wk; taJ :  
                                                     “vd;dNt fz%d;W tUle; njhl;Nl 
                   Vohz;L kl;Lf;F kpUf;Fq; fhyk;”      
                                     - ghythflk;   
NkYk;      
 3-7tajpy; cz;lhjy;  
 ghYk;NrhWk;cz;Zk; gUtj;jpy; cz;lhjy; 
 3-12 tajpy; cz;lhjy; vd %d;W fUj;Jfs; cs;sd. 
III fzk; Njhd;Wk; tpjk ; :                  
1. fh;g;gr;R+l;bd; fhuzkhf  
2. Iaj;jpd; njhlHghf 
3. khe;jNehapd; njhlh;r;rpahf fz  NehahdJ  Njhd;Wtjhf   
E}y;fs;  $Wfpd;wd.       
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1. fh;g;gr;R+L 
‘njhifahd fzq;fs; vy;yhk; fh;g;gr;R+L”  
                             - ghythflk;.  
 ‘R+L”vd;gij ‘clypd; ntg;gepiy” vd;W nfhs;Nthkhdhy; fUTw;w 
fhyj;jpy; jha;khh;fSf;F fpUkp njhw;wpdhy; (maternal infection) Ruk; Vw;gl;L> mJ 
gpwf;Fk; Foe;ijiaAk; ghjpg;gjhf nfhs;syhk;.   
khwhf ‘R+L” vd;gij gpj;jk; (m) moy; vd caph;j;jhJthf nfhz;lhy;> 
fUtpd; moy;jhJ khWghL fPo;f;fz;l tifapy; cz;lhfyhk;.  
1. Rf;fpyj;jpd; tpfw;gk;: 
2. Rf;fpy> RNuhzpjq;fspd; tpfw;gk;.  
3. fUTw;w jha;khh;fspd; czTKiw> nray;ghLfs; ,tw;wpd;       
tpfw;gq;fs;.  
Rf;fpyj;jpd; tpfw;gk;:  
fUTf;F moy;jhJtpid Nrh;g;gJ Rf;fpykhFk; mjid gpd;tUk; E}y;fs; 
njspthf $Wfpd;wd.  
je;ijapd; Ntl;ifahy; gpz;lk; fdypy; mbgl;L fzk; tUtjhf 
$wg;gl;Ls;sJ.  
 “ghuhd nfw;gntl;il kPUk; gf;Ftj;jpy; 
 Ntuhd tphpe;J ntspg; gl;L Nahdp tpOe;j njd;whw; 
 fhuhd gpz;lq; fdypyb gl;Lf; fhe;jpdpdhw; 
      $uha; fzRu nka;J nkd;Nwahd; $wpNdNk” 
    -jpUts;St ehadhH etuj;jpdrpe;jkzp 800     
Rf;fpy> RNuhzpjq;fspd; tpfw;gk; : 
ehjK« éªJÎ« Ïuz;L« nr®ªJ fyªJ ã‹W ntëæš ÂuSkhdhš fh‰W  
mdš, Ú® v‹w %‹W« Ïiz¤J kz v‹D« cUÎ, clyhš cæUkh», ehb 
eu«òfŸ Ã‹dš nfhz;L ój« Kjyhd j¤Jt§fŸ všyh« ml¡fkhæd. . thj«, 
Ã¤j«, ÁNy‰gd« %tU« m§F ÏUéid¡F« %y¡fhuzkhæ‰W.  
        fhZ»‹w ehj éªJ Ïuz;L§$b 
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 fyªJ ã‹W ntë¡FŸNs Âuz;ljh»š 
NgD»‹w fh‰wdš Ú® %‹Wkh» 
 ÃUÂénaD« cUÎ cl‰W æUkh» 
óZ»‹w ehb eu«gJÎkh» 
 ójnkhL j¤Jt§fnsš yhkh»š 
%Z»‹w thj Ã¤j ÁNy‰gdkhd 
 %tU« m§»Uéid¡F« %ykh¢Nr.  
                      - jhZé‹ r§»u Áªjhkâ (thfl Ehš)   
fzkhdJ G+h;tn[d;kq;fspy; nra;j jPtpidfis je;ijahfTk;> 
,g;gpwg;gpy; nra;Ak; jPtpidfis jhahfTk; mile;J “~af; Fkhud;” gpwf;fpwhd; 
vd;W $WfpwJ.  
       ‘rPhpa njhd;ik nra;j jPtpid je;ijahfg; 
  ghhpypg; gpwg;gpw; nra;j ghtNk jhajhfg; 
  Nghpar; raf; Fkhud; tpwe;jpyh fpw kj;jg;Ng 
      fhhpa nrtpypj; jhaha; ‘fzk;” ngw tsUk; ehspy;…. .  
                          - jd;te;jphp itj;jpak;                          
            ‘ghd;ik vd;w tpe;jq;Nf A+Wk;NghJ 
      ghAklh td;dpNahL thAjhNd” ; 
                       - mfj;jpah; ty;yhjp ehb E}y;.  
           ‘cd;dpa fh;g;gf; Fopahk; ntspapNy 
      gd;dpa ehjk; gfh;e;j gpUjptp 
      td;dpAk; thAT khapUQ; Rf;fpyk; 
            kd;dpa rkdha; tsh;f;F KjfNk”.  
- jpUke;jpuk;.  
fUtpw;F> tpe;JtpypUe;J - thjk;> gpj;jk; vd ,uz;L jhJf;fSk; cjfePh;> 
ehjk; ,tw;wpypUe;J fgKk; fpilf;fpwJ vd fUjg;gLfpwJ.  
mNj ghlypy;> 
 ‘cjfKjpu KWq;fdy; thAthy; 
 rpj FW kq;fq;fs; nra;J Kbj;jpLk;” vd Fwpg;gpLtjhy; 
cjfkhfpa ePh;> jP kw;Wk; thAtpd; jd;ikahy; nre;ePuhf khwp kw;w 
cly;jhJf;fshd Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; ,tw;iw cz;lhf;Fk; 
vd fUjg;gLfpwJ.  
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vdNt Rf;fpy> RNuhzpjq;fspd; FiwghL> cjfePhpd; FiwghL 
Nghd;wtw;why; fUtpd; caph;j;jhJfspy; xd;whd moy; ghjpg;giltjhy; fzk; 
Vw;gLfpwJ. ‘fh;g;gr;R+L’ vd miof;fg;gLtjw;Fk; mJNt fhuzk; vd fUjyhk;.  
fUTw;w jha;khh;fspd czT gof;ftof;fq;fs;: 
gÁÍldU¡F« jhŒ¡F ÁNy¤Jk« mÂfç¡F«NghJk;, Ú® nghU£fsh»a 
czÎfshY« Fb¡F« Ú®, Ú®Nt£if , gÁ v‹gd mÂfkhf jhia Õb¤jhš 
ftiyia jU« fz« v‹w NehŒ cz;lhF«. .  
 
nfhŸS« Ia gjhh;j;j« jz;zPh; gif 
Nt‹W jhf« grpfŸ äFªjpbš 
 Ûz;Lk; Ûz;Lk; érpdq;fshFjš 
M‹w NrŒ¡F« fzq;fshFNk.  
         -fh;g;gcw;gj;;jpfhz;l« thiy thfl«                         
fUTw;w jha;khh;fspd; czT gof;ftof;fq;fs;> nray;ghLfs; 
Nghd;wtw;why; jhapd; clypy; moy;jhJ ghjpg;gile;J mJ fh;g;ghraj;ijAk; 
ghjpf;Fk;. 
vdNt fUtpd; moy;jhJtpy; FiwghL Njhd;Wtjhy; mjd; cly; 
jhJf;fs; ghjpf;fg;gLfpd;wd. ,JNt ‘fh;g;gr;#L’ vd miof;f fhuzkhfTk; 
mike;jpUf;Fk;.  
2.Iaj;jpd; njhlHghf Njhd;Wk; tpjk;:                   
  ‘IaJ $bw; nwd;why;  
        mhpitah; Jaue;jd;dhy; 
    nra;a gw; GdyUe;jpr;  
        nrwpry Njhle;jd;dhy; 
     igau ty;FyhSk;  
        grpAldpUe;jjhYk; 
     Ja;aNjhh; Fotp fl;Ff;  
         fzq;fSe; Njhd;W kd;Nw”.  
- ghythflk;.  
 
IaJ $bw;nwd;why;: (Iak; - caph; jhJ) 
Iaj;jpd; ,aw;if epiyfs;> mjd; kpFFzk; Nghd;wtw;iw xg;G Nehf;Fk; 
nghUl;L fPo;fz;lthW njhFf;fg;gLfpd;wJ.  
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jd;ik:   
 jz;ik> nea;g;G 
 ke;jk;> tOtOg;G 
 nkd;ik> jpz;ik 
thOkplk; : 
 rkhdthA> ROKid 
 Mf;fpid> tpe;J 
 ehf;F> cz;zhf;F 
 nfhOg;G> kr;ir 
 FUjp> khh;G 
 euk;G> vYk;G 
 %is> ngUq;Fly;> fz;> fPy;fs; 
,aw;ifg; gz;G: 
 epiyj;jy; 
 nea;g;G  
 fPy;fspd; mikg;gpd; fl;Lfs; 
 nghiwAilik(grp> ePh;Ntl;if Jauk;> fyf;fk;>ntg;gk; 
Nghd;wtw;iw nghWj;Jf; nfhs;Sjy;) 
Ia kpFFzk;: 
  mf;fpdp ke;jg;gly; 
  tha;ePH Cwy; 
  Cf;fk; Fiwjy; 
  cly; fdkhf Njhd;WtJld; ntz;zpwj;ijAk;>  
  Fsph;r;rpiaAk; miljy;.  
  cly; Kw;Wk; cs;s fl;Lfs; jsuy; 
  ,iug;G> cg;gprk;> ,Uky;> kpFJ}f;fk; cz;lhjy;.  
mhpitah; Jaue; jd;dhy;: 
mhpit - ngz;fspd; gUtq;fspy; xd;W.  
20-25 tajhdJ kfsph; kfg;NgW milAk; nghJthd fhyk; vd;gjhy;> 
ghlypy; mhpit vd;w thh;j;ijia Nkw;nfhz;bUg;gij czuyhk;. mg;gUtj;jpy; 
kfsphpd; Jd;gq;fshd cly;eyf;FiwT> nghUshjhuf;FiwT Nghd;wit 
Foe;ijfSf;F gy ,lh;ghl;bidAk;> Fwpg;ghf fzj;jpidAk; cz;lhf;Fk;;.  
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nra;a gw;GdyUe;jp nrhpry Njhle;jd;dhy;: 
gy;NtWtifg;gl;l ePhpid mUe;Jtjhy; ryNjhlq;fs; cz;lhfp epiyj;J 
fzNeha; Njhd;Wk; vd;gJ nghUshFk;.  
mj;jifa ePhpd; jd;ik> Fbj;jYf;F Mfhj ePH vd rpj;jkUj;Jtj;jpy; 
$wg;gl;Ls;s fUj;Jfis fhz;Nghk;.  
ePhpd; jd;ik: (rpj;jkUj;Jthq;f RUf;fk;): 
ePuhdJ kdJf;F fspg;igAk;> epiwitAk; cz;lhf;FtJ kl;Lkd;wp 
cl;nfhs;Sk; cztpid ed;wha; clypw; gutr; nra;J clw;F td;ikiaj; 
jUk;. NkYk; cz;l fbd czTg;nghUl;fis nrhpg;gpf;Fk;.  
ePUf;F jdpFzk; ,y;iy. mJ jq;Fk; ,lj;jpd; NtWghLfshNyNa 
ntt;NtW Fzq;fis milfpd;wJ. ,jid>  
‘jz;zPh; Fznky;yhe; jhd; Nfs; klkapNy 
kz;zpd; Fzky;yhy; kw;Wz;Nlh? ’  
- Njud; nghUl;gd;G 
Mfhj ePh;: 
 ‘re;jpuh jpj;jh; tsp rhuhj ePh; GOJh;f;  
  fe;jkjp NrW fdg;gpiyA - jphpe;j ePh; 
  jq;FRit apy;yh ePh; rhw;Wkpit ];ehdgh 
  dq;fSf;fh fhTwpNeh ahk;” 
    - gjhh;j;j Fz rpe;jhkzp 
jpq;fs;> QhapW ,tw;wpd; fjpnuhsp;;; fhw;W ,itfs; mZfhjJk;; fpUkp> 
Jh;ehw;wk;> NrW jbj;jy;> rUF cjpuy;> Ritapd;ik vd;Dk; ,itfs; 
nghUe;jpaJk; Mfpa ePh;> Fspay;> Fbj;jy; ,itfl;F MfhJ. ,ij cz;zpd; 
Nehia cz;lhf;Fk; 
NkYk;> 
‘ Jiyahf; fpzNw fae;jpul;Lk; ”  
     - ,iwg;gpy;yh fpzw;WePh; fgg;gpzp cz;lhf;Fk;.  
           ‘ tsh;f;FQ; Ruj;ij rU$wy; ”   
    - rUF Cwpa ePh; Ruk; tsh;f;Fk;.  
           ‘ khwhf; FsNk tpahjpAz;L ”   
   - gad;gLj;jhj Fsj;JePh; tpahjp cz;lhf;Fk;.  
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mt;thW gy;NtWgl;l ePhpid mUe;Jtjpdhy; ryNjhlk; Vw;gl;L fzNeha; 
Njhd;Wk; vd;W $wg;gLfpd;wJ.  
igau ty;FyhSk; grpAldpUe;jjhYk;:  
#Yw;w ngz;fs rhptpfpj cztpid cz;zhjjhy; mth;fspd; cly;eyd; 
Fd;wp mJ Foe;ijfspd; tsh;r;rpiaAk; fzNeha; Njhd;Wtpf;Fk. ;  
IV. fzj;jpd; tiffs;(Types): 
gy;NtW E}y;fs; ntt;NtW vz;zpf;iffspy; fzj;jpidj njhFf;fpd;wd.  
 mNahj;jpjhrh; ghythflk; 24 tif - gf;fk; - 180; gjpg;G 1992 
1. tPf;f fzk;    
2. gpwf; fzk; 
3. me;jf fzk;    
4. ke;jhu fzk; 
5. vhp fzk;     
6. ePuhk fzk; 
7. Mk fzk;      
8. Kf;F fzk; 
9. %y fzk;    
10. Nguhk fzk; 
11. uj;j fzk;   
12. rpq;fp khe;j fzk  
13. ePhf;fzkhe;jk;     
14. mow;fzk; 
15. Ia fzk;    
16. khe;j fzk; 
17. ePh;f;fzk;     
18. gpuspf;fzk; 
19. #ypfzk;     
20. Ropfzk; 
21. kfhfzk;     
22. CJfzk; 
23. tus;fzk;    
24. nfhjpg;G fzk; 
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gps;isg;gpzp thflk; - 8 tif 
1. ePh; fzk;    5. tus; fzk; 
2. %yfzk;    6. rPjfzk; 
3. ,ja fzk;   7. kfhfzk; 
4. kyf;fzk;   8. Fz;lypa fzk; 
 gps;isg;gpzp kUj;Jtj;jpy; $wg;gl;Ls;s fzq;fs;-64 tiffs; 
1. ePh;fzkhe;jk;   33. mow;fzk; 
2. Ia fzk;   34. khe;j fzk; 
3. ePh;f;fzk;    35. gpuspf;fzk; 
4. #ypfzk;    36. . Ropfzk; 
5. kfhfzk;    37. CJfzk; 
6. tus;fzk;   38. nfhjpg;G fzk; 
7. tPf;f fzk;   39. gpwf; fzk; 
8. mf;fu fzk;   40. ke;jhu fzk; 
9. vhp fzk;    41. ePuhk fzk; 
10. ,uj;j fzk   42. Kf;F fzk; 
11. %y fzk;   43. Nguhk fzk; 
12. cyup fzk;   44. rpq;fp khe;j fzk; 
13. Mk fzk;   45. Rj;jp fzk; 
14. czf;F fzk;   46. ru;g;g fzk; 
15. cd;Nuhffzk;   47. rpj;ufzk; 
16. CJkhe;j fzk;   48. Rufzk; 
17. fug;ghd;fzk;   49. jdpRufzk; 
18. fsp;fzk;    50. mjpRu fzk; 
19. Fly;Nrhif fzk;  51. J}q;F fzk; 
20. FlNyw;w fzk;   52. njw;fj;jp fzk; 
21. vhp fzk;    53. njw;fj;J khe;j fzk; 
22. ,uj;j fzk   54. ePuhk;g fzk; 
23. %y fzk;   55. gl;rp fzk; 
24.  kNfe;jpu fzk;   56. ghy fzk; 
25. ke;jhu fzk;   57. %yhjhu fzk; 
26. Nkf fzk;   58. thA fzk; 
27. thNte;jpu fzk;   59. thyre;jpu fzk; 
    28. tp\ fzk;   60. tp\ePu; fzk; 
    29. tp\ghf fzk;   61. tp\ khe;j fzk; 
     30. tpujp fzk;   62. tPq;F fzk; 
     31. ntg;G fzk;   63. Fd;wp mf;fu fzk; 
     32. nghUK fzk;             64. KbNyhf fzk; 
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guuhr Nrfuk; ghyNuhf epjhdk; - 18 tiffs; ghly; :  
1. thj fiz   10. gpj;j fiz 
2. Ruf; fiz   11. mj;jpRu fiz 
3. twl;fiz   12. thyre;jpufiz 
4. kNfe;jpu fiz  13. J}f;F fiz 
5. mdw; fiz   14. tPq;F fiz 
6. ntSg;Gfiz   15. rj;jp fiz 
7. ,uj;j fiz   16. %yf;fiz 
8. fUq;fiz   17. kQ;rl; fiz 
9. epyf; fiz   18. ntg;G fiz 
[Ptul;rhkph;jk;> 8 tiffs; - MWKfk; gps;is mgpjhd rpe;jhkzp  
1. #ypfzk;    5. Kf;F fzk; 
2. Mkfzk;    6. Njiufzk; 
3. kfhfzk;    7. Ropfzk; 
4. fopfzk;    8. tws;fzk 
Mj;kul;rhkph;jk; vd;Dk; itj;jpa rhuq;f rq;fpufk;  - fe;jrhkp Kjypahh;; 
1. thj fzk;   13. gpj;j fzk; 
2. rpNyj;Jk fzk;   14. khe;j fzk; 
3. ePh;f; fzk;   15. gpusp fzk; 
4. #iyf; fzk;   16. Rop fzk; 
5. kfh fzk;   17. CJ fzk; 
6. twl;rp fzk;   18. nfhjpg;G fzk; 
7. tPf;f fzk;   19. gpwf; fzk; 
8. Mkf; fzk;   20. twl;rp fzk; 
9. Kf;F fzk;   21. Nghh;f; fzk; 
10. ,uj;j fzk;   22. er;R khe;j fzk; 
11. CJ khe;j fzk;   23. vhp fzk; 
12. ke;jhu fzk; 
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TV rhk;grptk; gps;is mfuhjpapd;gb  
fzkhdJ> khjh gpjhf;fspd; ehj tpe;JFs;slq;fpa thjhjp 
Njhlq;fspdpd;W cw;gj;jpahfpf; fUg;ghraj;Jr; rpRitg; gw;wp mr;rpRtpdJ 
vOtifj; jhJf;fSk; td;ikailAq; fhyj;J mij Nehahy; tUe;jr; nra;Ak; 
Neha;.  
,J jkpo; itj;jpag; gb Nehapd; Fzk; Fwp ,itfspd; ngahpl;L mNdf 
tpjkha;f; nfhs;sg;gLk;.  
A congenital disease of the child arising from the maturity of the bad humours 
inherited from the parents. It is an atrophy resulting from the enlargement of the bowels 
(tabes mesenterica). The disease progresses in several forms as the child advances in age.  
According to Tamil medical science it consists of different kinds and their names 
signify the symptoms characterising the disease as shown under: 
1. khe;j fzk;  -   Atropy resulting from indigestion.  
2. Kf;Ff; fzk;; - Atropy marked by prolapse of the anus due to straining.  
3. CJ fzk;;  - Atropy attended with a diffuse turgidity arising from the  
                            collection of morbid fluid.  
4. Ropf; fzk;      - Atropy followed by the whirling of the eyes.  
5. #iyf; fzk;; - Atropy characterisedby acute pain on the sides.  
6. Mkf; fzk;  - Atropy arising from nutritional disorders and marked by  
                            mucous in the stools.  
7.  %yf; fzk;;   -  Atropy associated with the heat of the lower rectum 
8.  #l;Lf; fzk; my;yJ fopf;fzk; - Atropy due to excess of heat in  the  
                                                                  system resulting diarrhoea.  
9.  thjf; fzk;  
10. gpj;jf; fzk;  -      Atropy caused by the three morbid humours  
    Of the system    
 11. rpNyl;Lkf; fzk; 
  
12. ePh;f; fzk; -   Atropy marked by the swelling of the    
                  extremities due to the collection of morbid fluid.  
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13. gpuspf; fzk; - Atropy attended with convulsion or fits and rolling of the  
      head  
14. tul; fzk;.  -  Atropy attended with convulsion or fits and  rolling of the  
      head 
15. nfhjpg;Gf;; fzk; -    Atropy following by inflammation of the alimentary tract.                          
16. gpuspf;; fzk; -      Atropy arising from congenital causes.  
17.; kfh fzk;  -   Atropy associated with aphthae and anemia.  
18. tPf;ff; fzk;  -  Atropy distingnished by diffuse swelling of the body.  
19. Nghh;f; fzk; -    Atropy attended with palpation of the heart    
                   and giddiness.  
20. ,uj;jf; fzk;  -      Atropy followed by haemorrhage internal or external.  
21. vhp fzk;  -     Atropy characterized by burning sensation    
                                all over the body and sleeplessness.  
22. ke;jhuf; fzk; -     Atropy peculiar to rainy season 
23. me;jff; fzk; -     Atropy attended with cerebral affections ending in death. 
24. CJ khe;jf; fzk; -  Atropy attended with indigestion and swelling of the  
                                               abdomen. 
25. tpl khe;jf; fzk;-  Atropy or another variety of mantha kanam 
26. Njiuf; fzk; -   Atropy associated with internal fever and  marked by  
      great  emaciation.       
V. fzj;jpd; nghJ Fzq;fs; : 
1. ghy thflk; $Wk;Nehapd; Fzq;fs; 
 Foe;ijfSf;F khe;j Neha; gyKiw te;J Kw;wpYk; 
Fzkilahky; ,Ug;gjhy; ,e;Neha; cz;lhFk;.  
 gpj;jkhdJ mjpfkhfp thAf;fs; jd; Ntiyia nra;a Kbahky; 
jLj;JtpLk;. mjdhy; Foe;ijfspd; clypy; Vw;gl;l #L ve;NeuKk; 
tplhJ fhZk;.  
 Ruk; fha;jy; 
 ,Uky; 
 %r;R thq;Fjy; 
 cly; Nrhh;tiljy; 
 tapW Nehjy; 
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 tapW fopjy; : 
 kyk; vz;nza; frpthdjhf ,Uf;Fk; 
 rPjkhf> ,uj;jkhf (m) ,uj;jKk;> rPjKk; fye;J  
Ngjpahjy; 
 ghy; Nghy ntz;zpwkhf fopjy; 
 Cz; fOtpa jz;zPh; Nghy; Ngjpahjy; 
 kytha; vhpr;ry; 
 kyk; ntl;ilahjy; (kyr;rpf;fy;) : 
 cr;rpapy; Fop tpOjy; 
 Kfk; Nrhh;tile;J fhZjy; 
 Fuy; fk;kyhf NgRjy; 
 if> fhy;> Kfk; twz;L fhZk; 
 mdy; tPRtJ Nghd;W cl;Ruk; fhzy; 
 tha;ehw;wk; 
 khh;G $k;G Nghy; vOk;gp fhzy; 
 ePh; RUq;fy; 
fzj;jpy; xd;Wld; xd;W njhlh;Gfsw;w gy FwpFzq;fs; njhFg;ghff; 
fhzg;gLfpd;wd. mjdhy; fzj;jpy; gy Neha; epiyfs; ,Ug;gjid mwpayhk. ; 
NkYk; nghJf;FwpFzq;fis gpujhdkhff; nfhz;L> fzj;jpd; rpwg;G 
Fzq;fSld; nghUj;jp (fzj;jpd; tiffs;) Nehapid fzpj;jy; rpwg;ghdjhFk;.  
gpw E}y;fspy; fhZk; fzj;jpd; nghJFzq;fis mwpe;J nfhs;Sk;NghJ> 
Nehapid Fwpj;j njspthd xg;GNehf;F nra;a KbAk; vd;gjhy; mjidAk; 
fhz;Nghk;;.  
ghythflk; E}ypd;gb ePh;f;fzkhe;jj;jpd; FwpFzq;fs;: 
 ,Uky;  
 %f;fpy ePh; tbjy; 
 ,il,ilNa tpl;L tpl;L fha;r;ry; ,Uf;Fk;  
 tapW nghUkp ,iuAk; 
 gytpjkhf NgjpahFk;.  
 fz; nrhUFk;.  
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 clk;G Kfk; Nrhh;e;J fhZk;  
 jiy Gul;ly;  
 kaf;fk;  
 [Ptul;rhkph;jk ; $Wk; Nehapd; Fzq;fs;: 
 Njfthl;lk; 
 tha;ehw;wk; 
 jiyRw;wy; 
 cs;Ruk; (my;yJ) 
 xU Ntis ntspRuk; (my;yJ) 
 tapw;wpd; Nky; RLjy; 
 kaf;fk; 
 twz;l kyk; 
,f;Fzq;fs; rfy fzj;jpw;Fk; nghJthf tUk; vd mwpf.  
mgpjhd rpe;jhkzp $Wk; Nehapd; Fzq;fs;: 
 khh;gpy; tPf;fk; 
 cl;Ruk; 
 Ruk; 
 twz;l kyk; 
 
cs;Ruk; Fwpj;j tpsf;fk;: 
mf];jpah; RuE}y; 300 - ‘rpj;jkUj;Jtk; - nghJ’ gf;fk; 57 - 6k; gjpg;G 
vd;w E}ypy; ‘RukNj fizajhFk;” vd $wg;gl;Ls;sJ. mjd; tpsf;fj;jpy; 
Foe;ijfSf;F Njhd;Wfpd;w vd;GRuk;> moy; Ruk;> khe;jRuk; Nghd;witfs; 
Foe;ijfis tUj;jkilar; nra;J> gpd;dh; fiz Nehapid gpwg;gpf;Fk;.  
fzk; - Ruk; njhlh;G : 
 fz;lh yh«Ngh Y£Ruk« 
 JyNk gåuz;lhz;L k£L« 
       jdjhŒ tUt§ FzäJNt.  
         - rpj;jkUj;Jtk; (nghJ) 
 ‘fiz Nehapy; cl;Rukhf fhAk;” 
 ‘fizapy; fhe;js; kyh; Nghd;w Ruk; fhZk;” 
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Nkw;fz;l Nkw;Nfhs;fs;> fzj;jpy; Ruj;jpw;Fk; gpw Neha; epiyfspy; 
fhZk; Ruj;jpw;Fk; NtWghL cz;L vd;gij njspthf $Wfpd;wd.  
(fhe;js; kyh; vd;gJ jP G+jj;Jld; njhlh;G nfhz;lJ. me;j kyhpd; my;yp 
,jo;fs; RUf;fkhdjhf fhZk. ; fiz NehapYk;> njhlh;e;J cl;Ruk; cs;s 
Foe;ijfs; cly; Nrhh;tile;J fhZtjhf nghJ FwpFzj;jpy; Fwpg;gplg;gLtJ 
rpwg;ghFk;).  
‘cl;Ruk;” vd;gJ gpw Ruq;fspypUe;J NtWgl;lJ. ,r;Ruk;> cly; td;ik 
Fiwe;j Ngh;f;F ntspf;F njhpahky; clypd; cs;Ns jfpj;J> Ruk; ,Ug;gJ 
Nghd;W fhzg;gl;L> Nrhfk;> kdj;jsh;r;rp> iffhy; Xa;r;ry;> cztpy; 
tpUg;gkp;d;ik> tha;f;Fkl;ly;> vg;NghJk; Ruk; fha;tJ NghypUj;jy;> cly; 
nkype;J nfhz;Nl nry;Yjy; vd;Dk; Fwp Fzq;fis gpwg;gpf;Fk;.    - 
rpj;jkUj;Jtk; - nghJ - gf;fk; - 36.  
TV rhk;grptk; gps;is mfuhjpapd;gb  
Neerkanamantham: A Kind of  dyspepsic diarrhoea in children charecterised by rumbling 
noise in stomach , frequent purging and vomiting with emaciation.  
                                          TVS dictionary P-1873 
Kanamantham: Digestive disturbance in children with fever and emaciation  
                                           TVS dictionary P -29 
1. Neerkanam: It is wasting disease charecterised by intermittent fever fissure of mouth , 
swelling of limbs , shining of parts. 
khe;j Neha; -  fzk; njhlHG : 
khe;jk; : jha; kw;Wk; Foe;ijfspd; czthjp (m) Fzthjp gof;f tof;fj;jpy;   
        Fw;wk; NehpLk;NghJ Foe;ijfSf;F Njhd;Wk; nrhpkhdf; NfhshWfs;>   
        mjidj; njhlh;e;j czTg;ghij njhlh;ghd cghijfSk; khe;j  
        Neha; vd;W miof;fg;gLfpd;wJ. 
    “ kªjkJ tuyhW nrhšyNfë® 
  khjNuhL ghyfU kUªJª Ôå 
 Nr®ªjnjhU ghšjåNy érªjh‹ nfhz;L 
  ÁWtU¡F cjp;u¤jpš kªj« g‰¿ 
 C®¤njOªj Âiuædhš éuz§nfhz;L 
  cŸéuz« gyNehÎ cwt jh» 
 rh®ªj ky« Á¡»aÂš Njhr Kz;lhŒ 
  jhNdK¥ò« khªj tif rh‰W NtNd ” 
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             - gps;is gpzp kU¤Jt« 
czTg;gof;fj;jhy; khe;jk; Njhd;Wjy;: 
 cz;Zk; cztpd; nrhpkhdj;jpw;F> 
 rkhdd; - thjk;> 
 mdw;gpj;jk; - gpj;jk;> 
 fpNyjfk; - fgk;> 
 Mfpa %d;wpd; ,ay;ghd msT Kf;fpakhdjhFk;.  
mdw;gpj;jk; -  czTg;nghUs;fspd; nrhpkhdj;jpy; Kjd;ik  
gq;F  tfpf;fpwJ.  
fpNyjfk;  -   cz;Zk; cztpid nkj;njd nra;Ak;.   
rkhdd;  -  Nkw;fz;l ,uz;ilAk; rkepiygLj;jp> rhpahd    
      nrhpkhdj;jpw;F cjTfpwJ. ,J nrayw;why; nrhpkhdNk 
       elf;fhJ.  
ke;jhf;fpdp: 
Nkw;fz;l %d;wpy; mdw;gpj;jj;jpd; td;ik Fiwe;jhNyh> fpNyjfj;jpd; 
td;ik mjpfhpj;jhNyh> rkhdthA jd; ,aw;if epiyapypUe;J jtwpdhNyh 
ke;jhf;fpdp cz;lhFk;. mjdhy; czTg; nghUl;fs; clNd nrhpg;gpf;fhky;> 
thAthy; taw;wpiur;ry;> Flypiur;ry;> tapw;Wg;gprk; vd;Dk; ,tw;iw cz;lhf;fp 
neLNeuk; fopj;J nrhpg;gpf;;Fk;. vdNt cztpd; rhuk; clYf;F fpilf;fhky; 
Nghfpd;wJ.  
 Nkw;fz;l FiwghLfshy; cz;lhFk; Foe;ijfspd; cly;> kd 
ke;jj;jpid khe;jk; vd rpj;j kUj;Jtj;jpy; miof;fgLfpwJ.  
VI. Neha; fzpg;G: (Diagnosis) 
Piniyari muraimai is a method of diagnosing a disease. Siddha system has a very 
unique method of diagnosis.  
  “Pini” means   =  Disease 
  “Ari” means  = Identify 
  “Muraimai” means   =  Method.  
This is based upon three main principles and Envagai Thervugal. The three main 
principles are, 
1. Poriyal arithal (Inspection) 
2. Pulanal arithal ( Palpation) 
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3. Vinathal ( Interrogation) 
 Physician’s ‘Pori’ and ‘Pulan’ are used as tools for examining the ‘Pori Pulan’ of 
the patients. The above principles correspond to the methodology of  
1. Inspection,  
2. Palpation and,  
3. Interrogation in modern medicine, in arriving a clinical diagnosis of the disease. 
1. Poriyaal arithal: (Inspection) 
Porigal are considered as the five senses of perception namely, 
1. Nose  
2. Tongue  
3. Eye   
4. Skin  
5. Ear 
 
 2. Pulanal arithal: (Palpation) 
  Pulangal are functions of five senses. They are, 
1. Smell  
2. Taste 
3. Vision 
4. Sensation of Touch                                                                                                     
5. Hearing.  
Vinathal: (Interrogation) 
Vinathal is asking the information regarding the history of the disease, its clinical 
feature etc. , from the patient or his close relatives who are taking care of him/her.   
 rpj;j kUj;Jtj;jpd; Neha;fzpg;gpy; gpd;tUk; fhuzpfs; Kf;fpa gq;F 
tfpf;fpd;wd.  
Nehahspiar; rhh;e;jJ 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
2. cly; jhJf;fs; (VO clw;fl;Lfs;) 
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3. vz;tifj; Njh;T  
Nehahspiar; rhuhjJ 
4. nghOJ 
rpWnghOJ  -  itfiw> tpbay;> vw;ghL> ez;gfy;> khiy> ahkk; 
ngUk;nghOJ - fhh;> $jph;> Kd;gdp> gpd;gdp> ,sNtdpy;>  
               KJNtdpy; 
5. Itif epyq;fs; : FwpQ;rp> Ky;iy> kUjk;> nea;jy;> ghiy.  
Nkw;$wpa fhuzpfspd; khWghLfis xd;Wld; xd;W xg;gpl;L Neha; 
fzpf;fg;gLfpwJ.  
1. caph; jhJf;fs; (Kf;Fw;wk;) 
ePh;f;fzkhe;jj;jpy; Kf;Fw;w tpfw;gk; 
thjk;> gpj;jk;> fgk; Mfpa %d;W jhJf;fspy; rkr;rPH epiyapy; cz;lhFk; 
NtWghLfis Nehahf cw;gj;jpahfpwJ.  
(m)  ‘eLq;fpaNjhh; gpj;jkJ Nfhgq; nfhz;L 
   ey;ythAit gw;wp aOj;jpf; nfhs;Sk;” 
 - ghy thflk; 
Kjypy; gpj;jNjhlk; ghjpg;gile;J (jd;dpiy tsh;r;rp mile;J) gpd;G 
tspFw;wj;jpd; njhopiyAk; (Ntw;Wepiy tsh;r;rp mile;J) ghjpg;gjhf 
nfhs;syhk;.  
 ,Nj fUj;ij ‘ke;jkyhJ thAtuhJ” - Neha;ehly; Kjy; ghfk; vd;w 
Njud; Nrfug;gh ghlyhy; ke;jj;jpdhy; thA cz;lhFk; vd mwpayhk;. NkYk; 
khe;jk; (ke;jk;) vd;gJ gpj;jj;jpd; jd;dpiy tsh;r;rp Fzk; vd mwpaNtz;Lk;.  
 (M)  ‘IaJ $bw; nwd;why;”        - ghy thflk; 
,jd; nghUs; Iaf;Fw;wk; jd;dpiyapy; tsh;r;rp miljy; vd;gjhFk;  
,Nj fUj;ij ‘ fgj;jpidad;wp fhrRthrk; fhzhNj” - (Neha;ehly; Kjy; 
ghfk;); vd;w Njud;Nrfug;gh ghlyhy; Iaf;Fw;wj;jpd; jd;dpiy tsh;r;rpad;wp 
fzj;jpd; FwpFzkhd fhrk;> Rthrk; tuhJ vd mwpayhk;.  
K¡F‰wtpf‰g« : 
moš mÂfkh» thÍit mO¤Â¡ nfhŸS« mjdhš moš jâtj‰F 
têæšyhkš Foªij¡F mÂfkhf #Lz;lh» clš fzfz¥ò V‰gL«.  
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                                             - gps;isg;gpzp kUj;Jtk; 
(2) ePh;f;fzkhe;jj;jpy; cly;jhJf;fspd; epiy: 
cz;lcztpd; md;drhukhdJ Flypy; cwpQ;rg;gl;L clw; jhJf;fshd 
rhuk;> nre;ePh;> Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; (m) RNuhzpjk; 
Nghd;wtw;iw Nghlzpf;fpd;wJ vd cly;jj;Jt E}y;fs; $Wfpd;wd.  
 ‘je;jpL euk;g njy;yhe; jhq;fpNa A+izg; gw;wp 
  ce;jpL kpuj;jnky;yh kKnjd Tz;Z kd;Nw” 
  - guuhrNrfuk; - ghyNuhf epjhdk; ghly;: 269 
vd;w ghlyhy; fiz Neha; cly; jhJf;fis ghjpf;Fk; vd mwpayhk. ; 
fizapy; cly; jhJf;fs; Nghlzpf;fg;gLtjpYk;> cUthf;fj;jpYk; rpukk; 
Vw;gLfpwJ vd;gjhy; Neha; jPtpuj;jpw;F Vw;g midj;J jhJf;fSk; (Rf;fpy> 
RNuhzpjk; cs;gl) thpirahf xd;wd;gpd; xd;whf ghjpg;gilAk; vd 
fUjg;gLfpwJ. Rf;fpyk;> RNuhzpjk; ,tw;iw Neubahf tpe;J> ehjk; vd;W 
nghUs; nfhs;shky;> cly; nry;fs; kw;Wk; cWg;Gfs; jd;idnahj;j cUtg; 
ngUf;fpw;F Kjyha; epw;Fk; cly; jhJ vd nghUs; nfhs;tJ rpwg;ghFk;.  
(3); vz;tifj; Njh;Tfs;: 
  vz;tif Nj®Î : 
     mf¤JW Nehia¡ fu¤jhk yf«Nghš 
    gF¤j¿Å® ehb¥gçr« - njhFj;jãw« 
 f£Ltifr; nrhšnkhêf;fz;fz;lky %¤Âu« eh 
  v£Ltif ahYk¿ Å®.  
nghwp> Gyd;fshy; mwpjy;> tpdhjy; Nghd;witfspd; %yk; kUj;Jth; 
mwpe;jtw;iw vz;tifj; Njh;Tfs; %yk; cWjpgLj;j Ntz;Lk;.  
 ‘ ehb ];ghprk; eh epwk; nkhop tpop 
  kyk; %j;jpukpit kUj;JtuhAjk;” 
- Neha;ehly; Kjy; ghfk;     
    ’Njba tpahjpf; nfy;yk; Njfj;jpy; ghpl;irAz;L 
  $bNa epw;Fnkl;L ghpl;irahq; $wf;NfsPh; 
  ehbNa njhl;lhw; Njfk; %j;jpuk; thh;j;ij fz;fs; ehf;F 
  ghbNa kyryq;fs; gy tz;zk; ghh;j;Jf; nfhs;Ns” 
      - rpj;j kUj;Jtkzpfs; 
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Nkw;$wpa ghlypd; %yk; ehb> ];ghprk;> eh> epwk;> nkhop> tpop> kyk;;> 
%j;jpuk; Mfpad kUj;Jthpd; MAjk; Nghd;wit vd mwpayhk;.  
1. ehb 
vz;tifj; Njh;Tfspy; gpujhdkhdJ. gpzpapid ehbahywpe;J 
kUe;J}l;LjNy rpwe;jJ vd;W rpj;j kUj;Jtk; $Wfpd;wJ. Mdhy; Foe;ijfspy; 
ehbeil rhpahf Njhd;whJ vd;gij fPo;fz;l ghlyhy; mwpayhk;.  
’nfhz;blNt faNuhfp fhrNuhfp 
 Fwpg;ghf rpw;wpd;gk; nra;j Ngh;fs; 
 mz;blNt jhpj;jpuh;fs; tpUj;jh; ghyh; 
 nfhz;blNt ,th;fspd; cWg;gpd; jhJ 
 $wNt KbahJ vth;f;Ff; fpl;Lk;. ” 
- Neha;ehly; Neha; Kjy;ehly; jpul;L 
vdpDk; fzj;jpy; gpj;jFw;wk; Kjd;ikahf ghjpj;J gpd; thj> fg 
Fw;wq;fSk; ghjpg;gjhy;> fPo;fz;l ehbeilahdJ Njh;thsuhy; ghpNrhjpj;J 
vOjg;gl;lJ.  
- gpj;jfgk; 
- gpj;jthjk; 
- thjgpj;jk; 
2. ];ghprk;: 
Nehahspapid njhl;L ghh;j;jypd; %yk; czug;gLk; FwpFzq;fs; MFk. ; 
ePh; fzkhe;j Nehapy; fPo;f;fhZk; FwpFzq;fs; mt;thW czug;gl;lJ.  
- tapW typ;> Ruk;> cl;Ruk; 
3. eh 
 Nehahshpd; ehf;fpidg; ghh;j;J czug;gLk; fzNehapd; FwpFzq;fshtd.  
- nre;ePh;j;jhJ Fiwe;J fhZjiy> eh ntspwpl;L ,Uj;jyhy; mwpayhk;.  
 
4. epwk;: 
 ePhf;fzkhe;j Nehapy; clw;fl;Lfs; td;ik Fiwe;Js;sij mwpa 
epwg;ghpNrhjid gad;gLk;.  
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     Njhypd; epwk;  -  ntspwpf;fhZjy; 
                     fWj;Jf;fhZjy; 
eh> fz;  -  ntspwpf;fhZjy; 
5. nkhop: 
ePh;f;fzkhe;jNeha; Foe;ijfspy; fgk; mjpfhpf;Fk; fhuzj;jhy; Fuy;fk;ky; 
Njhd;wp jho;e;J NgRth;.  
6. tpop: 
 tpopr;Nrhjidapy;> fzNehapd; fPo;f;fhZk; FwpFzk; czug;gl;lJ.  
- fPopik ntspwpf;fhZjy; 
 
7. kyk;: 
 fzNeha; Foe;ijfspy;> tpdhjypd; %yk fPo;fz;l FwpFzq;fs;mwpayhk;.  
- gytpjf;fopr;ry; 
8. %j;jpuk;: 
ePh;fzkhe;j Nehapy ePu;r;RUf;F fhzg;gl;lJ. Foe;ijfspy;>Ngjp ,Ue;jhy; 
clypd; ePh;j;Jtk; Fiwe;J ePh;;;;;;;tuj;J Fiwe;J fhZk;.  
9. ePh;f;Fwp: 
  ‘te;j ePh; fhpnail kzk; Eiu vQ;rnyd; 
  iwe;jpaYsit aiwFJ KiwNa 
                                - Neha; ehly; Kjy; ghfk; 
ePhpy; epwk;> kzk;> Eiu> vil> vQ;ry;> Mfpatw;iw Nehf;f Ntz;Lk;.  
nea;f;Fwp: 
Foe;ijfspd; ehbeil rhpahf fzpg;gjpy; rpukk; cs;sjhy;> nea;f;Fwp 
ghpNrhjid %yk; Nehahsh; vf;Fw;wj;jhy; ghjpf;fg;gl;Ls;shh; vd;gjid 
fzpf;fyhk;.  
 fzNehahspapd; rpWePiu Nrhjid tl;bypy; Cw;wp xsp kpFe;j ,lj;jpy; 
ePhpd; miyapy;yhj NghJ ey;nyz;nzaj;;Jsp tp;l;L ghh;f;fg;gl;lJ.  
rpyhpy; Mop Nghy; (Nkhjpuk;) gutpAk;> rpyhpy; Kj;JNghy; epd;Wk; 
fhzg;gl;lJ.  
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 ‘muntd ePz;bd; thjk; 
 MopNghw; gutpd; gpj;;jk; 
 Kj;njhj;J epw;fpd; nkhoptnjd; fgNk” 
- Neha; ehly; Kjy; ghfk; 
kUj;Jtk; 
1. Ntw;Wepiy tsh;r;rpaile;j gpj;jj;jpid jd;dpiyg;gLj;j Ntz;Lk; 
2. jd;dpiy tsh;r;rpaile;j Iaj;jpid rkg;gLj;j Ntz;Lk; 
3. gpj;jFw;wj;jhy; ghjpg;gile;Js;s thjj;jpidAk; rhpg;gLj;j Ntz;Lk;.  
4. td;ik ,oe;j clw;fl;Lfis td;ik milar;nra;Ak; tifapy; 
kUe;jspf;f Ntz;Lk;.   
Keeping in mind the need for bringing out an effective therapy for 
Neerkanamantham from Siddha system of Medicine, the author has undergone this 
dissertation work with Athimathura chooranam.  
The dosage of medicines are 
3 to 7 years - 750 mg  
8-12 years - 1. 5 gm  - b. d 
VII. Line of Treatment: 
 Siddha treatment is not only for complete healing but also prevention and 
rejuvenation. Saint Thiruvalluvar says about physician’s duty, study the disease, study the 
cause, treat subsiding way and do what is proper and effect.  
 ‘Neha; ehb Neha; Kjy; ehb mJ jzpf;Fk; 
  tha;ehb tha;g;gr; nray;.  
 ‘cw;whd sTk; gpzpasTq; fhyKq; 
  fw;whd; fUjpr; nray;. ” 
    - jpUf;Fws; 
 So it is essential to know the disease, the etiology, the nature of patients, severity 
of the illness, the seasons and the time of occurrence.  
Line of treatment is as follows.  
1. Kaappu (Prevention) 
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2. Neekkam (Treatment) 
3. Niraivu (Restoration) 
1.Kaappu (Prevention):  
Prevention and cure of the diseases are the basic principle of any medical system, 
but prevention is the main aim of Siddha system. Siddhars have described general 
preventive measures and special measures. (Which are applicable to diseases of certain 
organs) 
       And especially in Balavagadam, the preventive measures are explained in detail. 
Prevention of the disease of the child starts from the conception and goes on as the child 
grows up in intra uterine life and after delivery. Siddhars have dealt elaborately with the 
diet of pregnant women, her habit, the medicine to be taken in every month, her 
psychological conditions, and surroundings etc.  
2. Neekam: (Treatment) 
The aim of treatment is based on, 
a. To bring the three thodams into normal equilibrium state, emetics and purgatives 
are given. But considering physical condition of the children administration of 
purgatives and emetics is excluded from line of treatment.  
To treat the patient according to the symptoms by internal medicine Athimadhura  
Chooranam  
3. Niraivu: (Restoration) 
1. Reassurance of disease recovery was given to all patients.  
2. All the patients are advised to follow the life style that provides a disease free 
life.  
Pathiyam (Diet): 
 During the course of treatment, the drug is administered to the patients according 
to the nature of disease and the patients were advised to follow certain restrictions 
regarding diet and physical activities.  
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 This type of medical advice in siddha system of medicine is termed as 
“Pathiyam”.  
Importance of pathiyam is quoted as follows.  
‘gj;jpaj;jpdhNy gyDz;lhFk; kUe;J 
 gj;jpaq;fs; Nghdhy; gyd; NghFk; - gj;jpaj;jpy;  
 gj;jpaNk ntw;wpjUk; gz;bjHf;F Mjypdhy; 
 gj;jpaNk cj;jpnad;W ghH”    
- NjiuaH ntz;gh 
The patient with Neerkana Mantham advised to avoid cool drinks, cold water and 
exposure to chill weather and allergens (dust, psollens, and odours) ,During the course of 
treatment according to the drug administered to the patients and nature of the disease, the 
patients were advised to follow certain precautions regarding diet and physical activities. 
This type of medical advice in Siddha system of medicine is termed as Pathiyam.  
Siddhars advice regarding the diet regimen for Kaba patients is explained below: 
Siddhars advised to avoid certain food items in Kaba and Pitha noigal. They are 
given below:  
fj;jhp 
Nga;Gly; 
mtiu 
ghfy; 
fsh 
mj;jpf;fha; 
gPHf;;fqfha; 
fjypj; jz;L 
Ks;sq;fp 
fUk;G 
g+rpdpf;fha; 
cs;sp 
 ‘fj;jhp Nga;Gly tiu apUghfy; gUq;fsh fz;lfhhp 
  mj;jpf; fha;fSk; tUf;ifkhgaw;iw fiuahy; gPHf;fUk; - gpQ;RNtH 
 nkha;j;j R+uzq; fjypj; jz;Lfisg; g+Ksq;fp KUf;fUk;Gk; 
  mj;jpg; g+rpdpf; fhaUs;sp ts;spAq; fgj;NjhHf; fhzkhNk” 
 ‘Ntis kzj;jf;fhsp nkd; rPij rf;utHj;jp 
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   gPis triy Rf;F ngz;Rzq;fs; - Ntisapiy 
   nre;jspH fisf; fPiu nra;tH fgNjfH epjk; 
   te;jdpAzj;jhd; kfpo;e;J”- 
                      - gjhHj;j Fz rpe;jhkzp 
 Prevention methods: 
 ÃâaDfh éÂ 
 Âz;z äuz;LŸNs Á¡f tl¡f‰k‰ 
 ngz;â‹ghnyh‹iw¥ ngU¡fhkš cz;Z§fhš 
 Ú®RU¡F Nkh®bngU¡» neŒÍU¡» Íz;gth;j« 
 NgUiu¡»‰ NghNk gpzp.  
              - (Áj;j kUj;Jthq;r; RUf;fk;) 
The patients were advised, 
 To avoid exposure with cold weather .  
 To find out which agent makes allergy and avoid them.  
 To maintain hygienic procedure by avoiding contaminated food and 
water.  
 To avoid cold food stuffs, beverages etc.  
 To take nutritious diet especially spinachs, vegetable soups to improve 
immunity .  
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3. 2 MODERN ASPECTS 
RESPIRATORY SYSTEM: 
Respiratory tract; the tubular cavernous organs that allow that atmospheric air to 
reach the membranes across which gases are exchanged with the blood. The respiratory 
system extends from the nose to alveoli within the lungs.  
 There are 2 tracts of the respiratory system: 
Upper respiratory system  
       Lower respiratory system 
UPPER RESPIRATORY TRACT: 
  The upper respiratory tract consists of the nose, nasal cavity, paranasal sinuses and 
pharynx. It is responsible for:  
 The collection and delivery of air to the lungs 
 Warming, filtering and humidifying air.  
LOWER RESPIRATORY SYSTEM  
The lower respiratory tract includes the larynx, trachea, bronchi, bronchioles and 
alveoli(air sacs).  
ANATOMY OF THE UPPER RESPIRATORY TRACT 
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The Nose: 
This is the main conducting airway which is supported with many bones and 
cartilage.  
The Nasal Cavity: 
Contains "internal nares" which connect the nasal cavity to the paranasal sinus.  
This cavity is lined with pseudostratified ciliated columnar epithelium and coarse 
hairs near the vestibule (cavity near the nostrils) called vibrissae which protect the lungs 
from large particles and bacteria.  
The superior, middle and inferior nasal conchae subdivide the nasal cavity into 
three separate air pathways called the nasal meatus which is responsible for the main 
functions of gas conditioning.  
The Paranasal Sinuses: 
The paranasal sinuses contain sinuses from all the surrounding bones and are 
named accordingly: the frontal, ethmoidal, sphenoidal, and maxillary sinuses. All the 
sinuses communicate with the nasal cavity and their functions are to cleanse air, serve as 
chambers for sound resonance, and lighten the weight of the skull.  
They are all line with the same pseudostratified ciliated columnar epithelium 
lining as the nasal cavity.  
The Pharynx: 
  Commonly called the throat, it is used for inhalation/exhalation and swallowing 
food. Posterior to the nasal and oral cavities and extends inferior towards the lower 
respiratory tract.  
It contains skeletal muscles and flexible walls also coated with mucus for 
protection.  
It is split into three regions: the Nasopharynx, Oropharynx, and Laryngopharynx.  
Nasopharynx: 
The most superior region of the pharynx and is directly posterior to the nasal 
cavity and superior to the soft palate which forms a seal from the oral cavity.  
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On the lateral walls of the nasopharynx a pair of auditory tubes connects the 
Nasopharynx to the middle ear. This is to relieve pressure from the ear drum through the 
nasopharynx.  
Oropharynx:  
 Immediately posterior to the oral cavity.  
Laryngopharynx: 
This area is the inferior narrowed region of the pharynx. The area covered by this 
region is from the inferior part of the hyoid bone to the superior part of the esophagus. 
This region is also lined with non-keratinized stratified squamous epithelium for 
protection.   
RESPIRATORY INFECTION: 
Acute respiratory infections are one of the most common causes for morbidity and 
mortality in pediatric age group of developing countries. The clinical spectrum of 
respiratory infections ranges from common cold to life threatening illness such as 
pneumonia and its complications.  
COMMON UPPER RESPIRATORY TRACT INFECTION:   
The Upper respiratory tract includes the nasal passages sinuses pharynx, larynx, 
which serves as gateways to the trachea, bronchi, and pulmonary alveolar spaces.  
Upper respiratory tract infections represents the most common acute illness 
evaluated in the clinical setting. URTIs range from common cold typically a mild self 
limited cattarhal syndrome of nasopharnyx to life threatening illnesses such as epiglottis. 
Viruses account for most URIs. Bacteria primary infection or superinfection also causes 
URTIs.  
URIs is specifically manifested as cough, fever, Rhinitis, Pharyngitis, Epiglottis, 
Laryngitis, and Tracheitis.  
DEFINITION:  
Upper respiratory tract infections (URI or URTI) are the illnesses caused by an 
acute infection which involves the upper respiratory tract: nose, sinuses, pharynx or 
larynx. This commonly includes: tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, 
and the common cold.  
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COMMON URI TERMS ARE DEFINED AS FOLLOWS: 
 Rhinitis : 
Inflammation of nasal mucosa 
 Rhinosinusitis/Sinusitis :  
Inflammation of the nares and paranasal sinuses including frontal, 
ethmoid, maxillary and sphenoid.  
 Rhino Pharyngitis (Naso Pharynitis): 
Inflammation of the nares, pharynx, hyp[opharnyx, uvula and 
tonsils.  
 Pharyngitis:  
Inflammation of Pharnyx , hypopharnyx 
 Epiglossitis(Supraglossitis): 
Inflammation of superior portion of larynx and supraglottic  area.  
 Laryngitis 
 Inflammation of Larnyx 
 Laryngo Tracheitis: 
Inflammation of larynx trachea and subglottic area 
 Tracheitis: 
   Inflammation of trachea and subglottic area 
ETIOLOGY: 
Viral  Cause: 
Thefollowing virus can cause upper respirator tract infection 
 Adenovirus: 
Adenoviruses are nonenveloped DNA virus with diameter of 70 to 90 nm and 
spherical Icosahederal symmetry. Grown in tissue cultures if human origin. eg:Human 
amnion HeLa Around 33 serotypes are identified which causes infection. It causes 
infection of respiratory tract, intestine, eye.  
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 Rhinovirus: 
Rhinoviruses are over 100 serotyps of which H strain infects the human. It mainly 
causes infection of the upper respiratory tract and sometimes infects gastrointestinal tract 
also.  
 Orthomyxovirus 
 Paramyxovirus 
Paramyxoviruses are RNA viruses spherical or filamentous in shape 00 to 200 nm 
in size.  
 Coranovirus 
 Coranoviruses are ellipitical or spherical or filamentous enveloped with 
lipoprotein.  
 Reovirus 
Reo viruses are ether resistant icosahederal with double stranded RNA and causes 
mild respiratory and enteric diseases.  
Reoviruses are spherical 50 to 80 nm in diameter 
Bacteria Cause: 
 Staphylococci: 
Staphylococci are gram positive cocci, ovoid, non motile bacteria producing 
enterotoxina. Their deep infection produces sinusitis,tonsillitis, (upper respiratory 
infection) 
 Streptococci 
 Pseudomonas 
 Klebisella 
They are found in the mucous of the upper respiratory tract, intestine. They are 
non motile, capsulated grows in ordinary media forming colonies.  
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Fungal cause: 
Fungal are the normal inhabitants of the respiratory tract can also produce illness.  
Candida produces upper respiratory illness (Laryngitis) in immunocompromised 
individuals.  
MODE OF TRANSMISSION:  
The mechanisms of viral transmission are not well established, but most 
respiratory infection are thought to be spread by hand contamination with infectious 
secretions and subsequent auto-inoculation (nose-to-hand-to-hand-to-nose). Aerosol 
transmission and fomite transmission are also possible; prompt disposal of nasal 
secretions and handwashing are recommended interventions.  
 The mechanisms of viral transmission are not well established, but most 
respiratory infection are thought to be spread by hand contamination with infectious 
secretions and subsequent auto-inoculation (nose-to-hand-to-hand-to-nose). Aerosol 
transmission and fomite transmission are also possible; prompt disposal of nasal 
secretions and handwashing are recommended interventions.  
CLINICAL FEATURES COMMON TO UPPER RESPIRATORY TRACT 
INFECTIONS: 
 Cough- mild to moderate , hacking cough 
 Nasal discharge 
 Nasal congestion , Sneezing, sore throat 
 Fever – slight, present in children 
 Head ache 
 Myalgia- slight 
 Conjunctivitis occurs with adenoviral infections 
 Fatigue 
 Weakness 
 Malaise 
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RHINITIS: 
Causes of Rhinitis: 
 Rhinovirus,  
 Enterovirus 
 Coronavirus 
 Influenza A and B virus 
 PIV, RSV, and Adenovirus.  
Symptoms of Rhinitis: 
It is a inflammatory disorder marked by clear rhinorrhoea, malaise low or 
moderate fever nasal congestion. Examination reveals pale and edematous nasal mucosa 
congested nasal turbinates and nucoid rhinorrhoea. Conjunctival itching and redness are 
sometimes present.  
Children are affected on average six to eight of these upper respiratory infections 
every year.   
RHINOSINUSITIS: 
Inflammation of the nares and paranasal sinuses including frontal, ethmoid, 
maxillary and sphenoid.  
The term "common cold" refers to acute Nasopharyngitis (sometimes called acute 
rhinosinusitis), a mild, self-limited syndrome caused by viral infection of the upper 
respiratory tract mucosa. Cardinal features include malaise, nasal discharge and 
obstruction, sneezing and sore or "scratchy" throat.  
Viral causes:  
 Rhinovirus,  
 Enterovirus 
 Coronavirus 
 Influenza A and B virus 
 PIV, RSV, and Adenovirus.  
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 Bacterial causes: 
 Streptococcus pneumonia,   
 H influenza  
 Moraxella catarrhalis.  
 Other important pathogens include Group A streptococci and other 
streptococcal species.  
 Uncommon causes include C pneumonia, Neisseria species, 
anaerobes, and gram-negative rods.  
Symptoms of Rhinosinusitis: 
 Mucopurulent secretions: These may be present in the nares with both viral and 
bacterial sinusitis. Secetions may be thick or yellow.  
 Nasal discharge: This may be persistent and purulent, and sneezing may occur.  
Mucopurulent secretions are seen with both viral and bacterial infections. 
Secretions may be yellow or green, because thick, opaque, yellow secretions may be seen 
with uncomplicated viral nasopharyngitis.  
 Hyposmia or AnosmiaThis may occur secondary to nasal inflammation.  
 Facial or dental pressure or pain 
 Oropharyngeal Symptoms: Sore throat, Nasal obstruction may cause mouth 
breathing,  
 Halitosis 
 Cough: The cough may also be most prominent on awakening, occurring in 
response to the presence of secretions that have gathered in the posterior pharynx 
overnight.  
Daytime cough that lasts more than 10-14 days suggests sinus disease, asthma, or 
other conditions.  
Clinically significant amounts of purulent sputum may suggest bronchitis or 
pneumonia.  
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 Fever: Fever may occur concomitantly with purulent nasal secretions in persons 
with sinus disease. Fatigue or malaise: These may be seen with any URI.  
 Mucosal edema and erythema: When rhinitis is present, nasal mucosa may be 
inflamed. Typical findings include swelling and redness of the turbinates.  
 Nasal obstruction due to preexisting polyps or septal deviation:  
 Suppuration: 
Suspect an intracranial suppurative complication (eg, abscess) when the 
examination reveals signs such as proptosis, impaired extraocular movements, decreased 
vision, papilledema, changes in mental status 
RHINOPHARYNGITIS: 
Causes of Rhinopharyngitis: 
Adenovirus 
Enterovirus 
Coxsackie virus 
Parainfluenza virus. 
Symptoms of Rhinopharyngitis: 
 Pharyngeal symptoms include sore throat; Nasal obstruction may cause 
mouth breathing which may result in a dry mouth especially after sleep.  
 Cough : results from upper airway cough syndrome related to nasal 
secretions (post nasal drip) 
 Nasal symptoms include rhinorrhoea, congestion or obstruction of nasal 
breathing, sneezing.  
 Headache 
 Conjunctivitis is common with adenoviral and other viral infections.  
 Fever 
 Malaise or fatigue  
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NASOPHARINGITIS OR COMMON COLD:  
The term "common cold" refers to acute Nasopharyngitis (sometimes called acute 
rhinosinusitis), a mild, self-limited syndrome caused by viral infection of the upper 
respiratory tract mucosa. Cardinal features include malaise, nasal discharge and 
obstruction, sneezing and sore or "scratchy" throat. 
 Common cold is the most frequent medical problem in childhood and is usually 
due to upper respiratory tract with 
    Adenovirus 
    Infuenza 
    Rhinovirus 
    Parainfluenza 
    Respiratory syncitial virus. 
SYMPTOMS: 
    Fever  
    Thin nasal disharge 
    Cervical lymph nodes may enlarge 
    Nasopharyngeal congestion 
    Nasal obstruction 
PATHOGENESIS:  
 Viruses that cause the common cold are spread by small-particle aerosols, large-
particle aerosols, and direct contact. Although the different common cold pathogens can 
pre-transmission appear to be more efficient than others for particular viruses. In contrast 
to rhinzoviruses and RSV, influenza viruses appear to be most efficiently spread by 
small-particle aerosols.  
 The respiratory viruses have evolved different mechanisms to avoid host defenses. 
Infection with rhinoviruses and adenoviruses result in the development of serotype-
specific protective immunity. Repeated infections with these pathogens occur because 
there are a large number of distinct serotypes of each presented on the surgace of the virus 
and thus behave as though there were multiple viral serotypes. The interaction of corona 
viruses with host immunity is not well defined, but it appears that multiple distinct strains 
of coronaviruses are capable of inducing atleast short-term protective immunity. The 
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parainfluenza viruses and RSV each have a small number of distinct serotypes. 
Reinfection with these viruses occurs because protective immunity to these pathogens 
does not develop after an infection. Although reinfection is not prevented by the adaptive 
host response to these viruses, the severity of subsequent illness is moderated by pre-
existing immunity.  
 Viral infection of the nasal epithelium can be associated with destructionof the 
epithelial lining, as with influenza viruses and adenoviruses, or there can be noapparent 
histologic damage, as with rhinoviruses, RSV, and coronaviruses. Regardless of the 
histopathologic findings, infection of the nasal epithelium is associated with an acute 
inflammatory cytokines and infiltration of the mucosa by inflammatory cells. This acute 
inflammatory response appears to be responsible, at least in part, for many of the 
symptoms associated with the common cold. Inflammation can obstruct the sinus ostium 
of Eustachian tube and predispose to bacterial sinusitis or otitis media.  
ALLERGIC RHINITIS:  
Allergic is an allergic inflammation of the nasal airways. It occurs when an 
allergen , such as pollen , dust or animal dander( particles of shed and hair) is inhaled by 
an individual with a sensitized immune system.  
SYMPTOMS: 
 Rhinnorrhoea (excess nasal secretion), 
 Itching 
 Nasal congestion and obstruction 
Characteristic physical findings include 
 Conjuctival swelling and erythema 
 Eyelid swelling  
 Lower eyelid venous stasis , swollen, nasal turbinatesstasis 
 Middle ear effusion.  
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COMPLICATIONS OF URTIS: 
 Pharynigitis/tonsillitis 
 Otitis Media 
 Sinusitis and/or peri-orbital cellulitis 
 Croup/laryngitis 
 Lower Respiratory Tract Infection (e. g. bronchiolitis or pneumonia) 
 Asthma or viral induced wheeze 
         SYMPTOMS AND SIGNS SUGGESTIVE OF SERIOUS ILLNESS: 
 High fever, fever > 72 hours, delayed onset of fever 
 Severe headache 
 Upper airway obstruction – stridor, drooling 
 Lower airway – dyspnoea, tachypnoea 
         SIGNS SUGGESTIVE OF COMPLICATIONS 
 Exudative tonsillitis 
 Tender anterior cervical lymphadenopathy 
 Otalgia, otorrhoea, hearing loss 
 Tenderness over sinus area 
 Dyspnoea and Tachypnoea, pleuritic chest pain 
 Wheeze 
 Neck stiffness 
 DIAGNOSTIC TESTS FOR UPPER RESPIRATORY TRACT INFECTIONS 
 Complete blood count 
 Haemoglobin 
 Total count and differential count 
 Erythrocyte sedimentation rate 
 Absolute eosinophil count (AEC) 
 C-reactive protein levels 
 Temperature 
 Gramstain for pathogens 
 IgE levels 
 Histamine levels 
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OTHER RISK FACTORS FOR URTI: 
 Contact: Close contact with small children who frequent group settings, such as 
school or daycare, increases the risk of URI.  
 Travel: The incidence of contracting a URI is increased because of exposure to 
large numbers of individuals in closed settings.  
 Smoking and exposure to second-hand smoke: These may alter mucosal 
resistance to URI.  
 Immunocompromise that affects cellular or humoral immunity: This 
increases the likelihood of contracting a URI.  
 Anatomic changes due to facial dysmorphisms,  
 Carrier state: Some people are chronic carriers of group A streptococci. Such 
individuals may have repeated URIs.  
DIET: 
 Fluid intake: Increased fluids are warranted to replace insensible losses and 
reduced oral intake.  
 Probiotics: Antibiotics alter the gastrointestinal flora, and some foods may not be 
as digestible for days or weeks after antibiotics are used. Consumption of yogurt 
containing active cultures has been advocated as an aid to restoring normal flora 
after antibiotic therapy.  
 Chicken soup increases the clearance of nasal mucous.  
 Drink lots of fluids (water, fruit juice, tea, clear soup broths and non-caffeinated 
carbonated beverages).  
Treatment 
 Antibiotics 
 Anti-virals 
 Anti pyretic 
 De- congesant 
 Anti – histamine 
 Anti tussive 
 
 
 
42 
 
PREVENTION 
   Frequent hand wash especially after touching  doorknobs.  
  Limiting the child’s contact with people who may be sick, especially if 
your child is very young or especially at risk for getting sick.  
  Frequently wash toys, pacifiers, and other items that children tend to put in 
their mouths.  
  Cover your mouth and nose when coughing or sneezing, and teach your 
children to do the same.  
  Special attention should be paid to these infection-control methods in 
situations where children are in large groups, such as preschools and day-
care centers.  
 Practicing good hygiene is very important. As the foods rich in simple 
sugars increases the osmotic load they should be avoided to children.  
 Rehydration therapy for the replenishment of water and electrolytes lost in 
stools should be given for children.  
 Probiotics and Zinc supplementation may be given.  
 Intake of highly nutritious diet for increasing immunity and decreased 
suspectibility of infections in children.  
 Inhale warm moist air. Use a humidifier, take showers or put a pan of 
water on your radiator.  
  Practice mild exercise regularly.  
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3. 3 DRUG REVIEW 
Scientific Review of Athimathura Chooranam  
       
mÂkJu¢ Nuz« 
 
      mÂkJu nkyKl‹ yt§f¥ g£il 
 ahdr© gfbkh¡F nfh£lª jhD« 
      éÂÍlnd R¡FŠÓ ufK K¤j« 
 éjéjkhŒ tW¤Âo¤J¥ bgho¤J¡ bfh©L 
      rÂæUnl r®¡fiuÍ§ Tl¢ nr®¤J¢ 
 rfyÃŸis aUªÂlnt rgy khF« 
     kÂEjšnr® bg©zunr fzK« nghF« 
 kh¿tU§ fhŒ¢rbyyh khWª jhnd.  
3. 3. 1 mÂkJu« Glycyrrhiza glabra,Linn.  
English Name : Jequitity, Indian (or) Jamaica liquorice 
Sanskrit Name : Yasti-madhukam 
Family Name : Fabaceae 
Part Used : Root 
Suvai : Sweet 
Thanmai : Seetham 
Pirivu : Sweet 
            Actions             :     nfhiHaf‰¿, cŸsHyh‰¿, kyäs¡».                     
3. 3. 1. 1 General Charectristics: 
   f¤Âaç K¥Ãâahš tUò© jhf§ 
f©nzhŒ c‹ khj«é¡fš  tèbt©FZl« 
Ã¤jvY« òU¡»ç¢ ru«M t®¤j« 
Ã¤jkj _®¢irél ghf« bt¥gª 
j¤ÂtU thjnrhâj§fh khiy 
rUtél§ fhäanehŒ jhJe£l§ 
FU¤ÂUkš MÁa§f« ÏjœnehŒ ÏªJ 
              Fa¥ òQ«ngh« kJfbkd¡ TW§fhny.  
     - gjh®¤j Fzés¡f« 
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 ÏJ Ia¤jhš c©lhF« nfhiHia Ïsf¢ brŒÍ«. Ô F‰w¤Â‹ t‹ikia jhH 
brŒÍ«.  
3. 3. 1. 2 Chemical Constituents: Quercetin, Glucoside, Kaempferol, Astragalin, 
Licuraside, Licoflavonol, Glycyrin, Methyl Olean II, Glycyrrhetol, Triterpenoid, 
Prunetin, Glycerol, Sugars,  Asparagin, 7-Lydroxy-41 Methoxy is favone (formetin), 4-
Methy coumarin, Saponeritin (isovitexin)  diene-3 (Databases on medicinal plants used in 
ayurveda vol-3. ) 
3. 3. 1. 3 Pharmacological Action- Antimicrobial, Antiviral, Anti-inflammatory, 
Antipyretic (Jn of ethnopharma Vol. 91 7ss2-5 Apr 2004, pg (361-365), (Databases on 
medicinal plans used in ayhurvedha vol-3. )  
Antimicrobial activity - The activity guided fractionation of ethanolic extract from the 
roots of Glycyrrhiza glabra and subsequent phytochemical analysis resulted in identifying 
glabridin as the active constituent and hispaglabridin B as inactive constituent against 
Mycobacteriumtuberculosis. (V. K. Gupta et al. / Journal of Ethnopharmacology 116 
(2008) 377–380 ) 
Anti-inflammatory and antipyretic activity -Glabridin has been known to have a 
variety of beneficial effects including antimicrobial, anti - inflammatory, 
antiatherosclerotic, and antinephritic activities. Glabridin, an isoflavan from licorice root, 
inhibits inducible nitric-oxide synthase expression and improves survival of mice in 
experimental model of septic shock.( Kang JS et al J Pharmocol exp Ther 2005 Mar; 
312(3):1187-94. Epub 2004 Nov 10 (Fuhrman et al. , 1997; Yokota et al. , 1998; Zhou et 
al. , 2004).  
3. 3. 2 Vy« (Elettaria cardamomum,Maton. ) 
English Name   :   Candamom Seeds 
               San                   :      Ela 
Family Name    :     Zingiberaceae 
Part used           :      Seed 
Suvai            :      Acrid 
Thanmai            :       Veppam 
          Pirivu            :       Acrid 
          Action              :       bt¥gK©lh¡» 
                              mf£LthŒtf‰¿ 
                               gÁ¤Ô¤ö©o 
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 3. 3. 2 . 1 General Charectristics:  
            kythj nkhL tæ‰W¡ bfhÂ¥ò 
 ry_wš thæå¥ò jhfª ryngÂ 
 nt®¡Fª jiynehŒ äF%£il iaaäit 
 ngh¡FŠÁ‰ nwy« òfš.  
                              - gjh®¤j Fzés¡f«  
            ÏUkš, fê¢rš, Ú®RU¡F, beŠÁ‹ nfhiHf£L Ïitfis ngh¡F«. 
mHiy M‰W«.  
3. 3. 2. 2 Chemical Constituents: 
        Seeds:   Feruliacid, Vanillic, Caffeic Acid , P-Coumaric , Salicylic Acid 
        Oil:    Borneol, 1,8 – Cincole Linalytacetate , P-cymene, Nerol Myrcene , X- Pinene                        
Sabinane, Limonene (Variyar & Bandyopadhyas Speces Arom (50ps, 1995, 4, 129) 
3.3.2.3 Pharmacological Action: 
Analgesic effects -An investigation of the analgesic activity of the oil extracted 
from commercial Elettaria cardamomum seeds using p-benzoquinone as a 
chemical stimulus proved that a dose of 233microL/kg of the oil produced 50% 
protection against the writhing (stretching syndrome) induced by intraperitoneal 
administration of a 0. 02% solution of p-benzoquinone in mice. ( al Zuhair H, el 
Sayeh B, Ameen HA, et al. Pharmacological studies of cardamom oil in animals. 
Pharmacol Res 1996;34(1-2):79-82. ) 
Anti-inflammatory activity- A comparative study of the anti-inflammatory activity of 
the oil extracted from commercial Elettaria cardamomum seeds, in doses of 175 and 
280microL/kg and indomethacin in a dose of 30mg/kg against acute carrageenan-induced 
planter edema in male albino rats was performed, which proved to be marked.  
Anti-microbial activity - Essential oil from cardamom was evaluated to have some 
inhibition for each of the test strains that included: Listeria monocytogenes, 
Staphylococcus aureus, Escherichia coli O:157:H7, Yersinia enterocolitica,-( Elgayyar 
M, Draughon FA et al. Antimicrobial activity of essential oils from plants against selected 
pathogenic and saprophytic microorganisms)  
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Antioxidant effects - Cardamom has medium levels (50-100mg) of antioxidant phenolics 
and flavonoids. Total phenolics were measured biochemically and flavonoids were 
measured as a sum of quercetin, kaempferol, luteolin and pelargonidin. (J Food Prot 
2001;64(7):1019-1024 , J Assoc Physicians India 1998;46(8):708-710 ) 
3. 3. 3  Ïyt§fg£il (Cinnamomum verum, Presl. )
 English name  :   Cinnamon 
 Sans             :   Twak 
 Family             :   Lauraceae 
 Part used         :   Bark 
 Suvai             :   Acrid, Sweet 
Thanmai          :   Seetham  
 Pirivu       :   Sweet 
 Action            :   bt¥gK©lh¡» 
                            mf£LthŒtf‰¿ 
 3. 3. 3. 1 General Charectristics : 
            jhJe£l« ngÂ rUtél khÁanehŒ 
 ój»u fŠÁyªÂ¥ ó¢Áé£L – rhÂél 
 kh£LÃiw¥ nghoU« yhjanehŒ¡ T£lkw 
 nth£L Ãy§f¤ jç.  
                                       - gjh®¤j Fzés¡f«  
             ÏJ Ïiu¥ò, ÏUkš, tæ‰W fL¥ò Ïitfis ngh¡F«. 
3. 3. 3. 2 Chemical Constituents:  Linalool, Cinnamic aldehyde, Eugenyl Acetate, 
Eugenol, Benzaldyhyde, Caryophyllene, Phellandrene, Pinane, Cymene, Safrole, 
Geraniol,  Cinnazeylanin, Proanthocyanidin, Dipentenoids, Benzelbensoate, Cinncassiol.  
3.3.3.3 Pharmacological Action – Antiallergic, Antipyretic, 
Antibacterial,Antimicrobial(Databases on medicinal plants used in ayurveda vol-4 ) 
Cinnamon has a broad spectrum of medicinal and pharmacological application 
(Parthasarathy et al., 2008). Cinnamon possesses various biological activities such as 
antioxidant, antimicrobial, antidiabetic and antiallergic. Cinnamon oil showed an 
inhibitory effect against the Gram-positive bacteria Bacillus cereus, Micrococcus luteus, 
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Staphylococcus aureus and Enterococcus faecalis, Gram-negative bacteria Alcaligens 
faecalis, Enterobacter cloacae, Escherichia coli and Pseudomonas aeruginosa .( 
Kamaliroosta L. et al Journal of Medicinal Plants Research Vol. 6(4), pp. 609-614, 30 
January, 2012)    
 
 3. 3 . 4  r©gfbkh¡F (Michelia chambaca Linn) 
       English name   : Golden or yellow champaka , champak 
 Sans         :   Champaka 
 Family name    :  Magnoliaceae 
 Part used        :   Flower. 
 Suvai          :    Bitter 
      Thanmai        :   Veppam  
 Pirivu          :   Acrid 
      Action          :         mf£LthŒtf‰¿, 
                                     ÁWÚ®bgU¡», 
                                               bt¥gK©lh¡» 
3. 3. 4. 1 General Charectristics :  
             thjÃ¤j k°ÂRu kh«kfŠ R¤jRuª 
  jhJeZl§ f©zH‰Á jh§fnt – khnjnfŸ 
  Â©òW« iffë¥ghª Â›az K£odnr® 
  r©gf¥ ótj‰F jh‹.  
                                           - gjh®¤j Fzés¡f«  
                          - thjÃ¤jRu«, f©mHiy ngh¡F«. 
3. 3. 4. 2 Chemical Constituents: Quercetin, micheliolide, eicogenoiec, magnoflorine, 
Flavonoid glycoside, -Sitosterol, Unsaturated aliphatic ketones, Hydrocarbons, 
Aldehydes, Phenolics,Saponins,Sterols,Tannins , Mono sesqueterpenes . 
Refined seed oil of M. Champaca was found to be 24. 2% palmitic, 5. 8% stearic, 
66. 2% oleic, and 3. 9% linoleic acids.( Databases on medicinal plants used in ayurveda 
vol-2) 
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3. 3. 4. 3 Pharmacological Action- 
              Anti-inflammatory and antipyretic activity- Methanolic extracts of the flowers 
of M. champaca, I. brachiata and R. cana exhibited significant antiinflammatory activity 
against cotton pellet granuloma in rats at a dose level of 100 mg/kg body weight. ( Ind. J.  
Exp. Biol. 1997; 35 (12) :1310-4)  
 3. 3. 5 nfh£l«  - Costus speciosus,koenig ex Retz. ) 
       English name   :  Spiral flag  
  Sans           :   Koshtam 
  Family name    :  Zingiberaceae 
  Part used          :  Rhizome(tuber) 
  Suvai           :  Bitter, viruvirupu 
 Thanmai         :  Veppam   
  Pirivu             :   Acrid  
         Action           :     gÁ¤Ô¤ö©o 
                                  nfhiHaf‰¿ 
                                 bt¥gK©lh¡»  
                                             éa®itbgU¡» 
3. 3. 5. 1  General Charectristics :  
             Â£ofÎ yhfLfsŠ br‹å ehthŒ 
    br¿Ãâbt« gij¥òjh t®¤jj _ij 
 K£obaU KiséuzŠ Rthr fhr 
                _of¤njh luÎku él§f© nkf¡ 
 f£oa# fšètl ghf« ójfz« 
     ghy »ufbkhL jhJe£lª 
 brh£oxU ÃuäÃ¤j äit bahU§nf 
      bfhiyÍ«éu Qç¡F f¥ngwhnk  
                                         - gjh®¤j Fzés¡f«  
Ïjdhš Ru«, Ïiu¥ò, thÍ nghF«. f©, tæW, jiy, thŒ Ï›él§fëš 
c©lhF« nehŒfŸ nghF«.  
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3. 3. 5. 1 Chemical Constituents: Rhizomes contains diosgenin, costuside,  prosapogenin 
B of dioscin, diosgenone, cycloartanol, 25-en cycloartenol octacosanoic acid, -Sitosterol,  
spirostanol glycoside (steroidal saponins), gracillin, palmitic acid, stearic acid,oliec acid, 
arachidic acid, methylhexadeconade. 
3. 3. 5. 2. Pharmacological Actions -Anti-inflammatory activity, Antipyretic activity:( 
Databases on medicinal plants used in ayurveda vol -7) 
Phytochemical And Antimicrobial Studies -  secondary metabolites are alkaloids, 
flavanoids, cardiac glycosides, saponins, sterols and tannins, coumarin, phenols and 
carboxlic acid Anthraquinone Anthra-glycosides, Valepotriates, Arbutin, Essential oils -  
(Mallikharjuna P B et al JChem. , 2007, 4(4), 510- 518. )  
Anti-inflammatory and antipyretic activity- Antiinflammatory antipyretic The 
ethanolic extract of the rhizome of Costus speciosus possesses anti-inflammatory and 
antipyretic properties. Antiinflammatory property was studied in carrageenan induced 
paw edema and cotton pellet induced granuloma formation. Significant antiinflammatory 
effect was found against carrageenan induced edema formation in rats at a dose of 800 
mg/kg and against cotton pellet granuloma formation in rats at doses of 400 mg/kg and 
800 mg/kg. The antipyretic property was studied in yeast-induced pyrexia in rats. The 
antipyretic effect was only minimal and was observed only at 800 mg/kg dose. 
3. 3. 6 R¡F (Zingiber officinale. Rosc) 
Family         : Zingiberaceae  
Sans           :       Nagaram 
English Name   : Ginger 
Tamil Name              :      Sukku, Inji, Allam, Lakottai, Inci Chu 
Part used   : Dried rhizome 
Suvai        :       Acrid 
Thanmai       :       Veppam 
Pirivu        :       Acrid  
Action         :         bt¥gK©lh¡» 
                                                 gÁ¤Ô¤ö©o 
                                     mf£LthŒtf‰¿ 
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3. 3. 6 . 1 General Charectristics :  
 Jiykªj« beŠbrçÎ njhõ«V¥ g«mHiy 
 _y« Ïiu¥ÃUkš _¡FÚ® - thyfg 
 njhõ« mÂrhu« bjhl®thj F‹k«Ú®¤ 
 njhõ« k«ngh¡FŠ R¡F.  
Ïiu¥ò, ÏUkš, fê¢rš, Únu‰w«, tæ‰W c¥Ãr«, tæ‰W F¤jš nghF«.  
Pharmacological Action -Anti Inflammatory, Anti Pyretic, Analgesic, Anti depressant, 
Anti rhinoviral ,Anti Oxidant  
3. 3. 6. 2 Chemical Constituents: Volatile Oils ( bisabolene, borneol, Camphene, Cineol, 
Citral, Citronelrol, Seranial, limonene, linalogl, Phellandrene, Zingibereene, Zingiberol) 
The aromatic principles are bisabolene & Zingiberene,  Calcium, Capsaicin, Chrcumin, 
high in iron and Calcium, linoleic acid Magnesium, Phosphorous, Potassium, riboglavin, 
Vitamin B & Vitamin C, Zingibain, Ginger has proteases (GP-I and GP-II) that are 
similar to disetive aids bromelain  (Databases of medicinal plants in ayurveda vol -5) 
3. 3. 6. 3 Pharmacological Action- 
Antibacteraial Activity 
Zingiberene enhances antibacterial and anti-inflammatory actions and it is thought 
to assist other antibacterials such as antibiotics by up to 50%. Dried Ginger’s ability to 
redue inflammation is due to its neutralizing action upon free radicals which are known to 
contribute to the problem. Finally, Ginger contains over it antioxidant constitulents the 
combined action of which have been regarded as being more powerful than vitamin C.  
Anti-infammatory Activity 
 Dried ginger extract inhibited carrageenan-induced paw swelling and was an 
active as aspire. Essential oil of ginger injibited chronic adjuvant arthritis in rats ginger 
and its pungent components are dual injibitors of arachiodonic acid metasolism. That is, 
they inhabit both cycloosygen use (Prostagland in Synthetase) and (ipoxysenuse enxymes 
of the prostaglandin and Leukobriance biosynthetic pathways.  
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Antipyretic Activity 
 Dried ginger extract given orally reduce fever in rats by 35%, while the same dose 
of aspirin was effective by 15%. The antipyretic activity of 6 Shogaol urel 6-gingeroil has 
also been observed.  
Anvioxidiant Activity 
 Extracts of dried ginger have pronounced antioxidant activity comparable to that 
of synthetic antioxidant preservatives.  
3. 3. 7 e‰Óuf« (Cuminum cyminum. Linn ) 
Family         :    Apiaceae 
Sans           :    Jirlga  
English Name              :    Cumin seeds 
Part used   :    Seed  
Suvai          :    Acrid,sweet  
Thanmai        :    Thatpam 
Pirivu         :    Sweet  
Action         :  mf£LthŒtf‰¿ 
                             bt¥gK©lh¡» 
                              Jt®¥Ã 
                             gÁ¤Ô¤ö©o 
3. 3. 7. 1 General Charectristics :  
                thÍbthU ehÁnehŒ t‹Ã¤jŠnruhJ 
  fha« be»HhJ f©FëUª öaky®¡ 
  fhusf¥ bg©kæny iff©l Â¤jidÍª 
  Óuf¤ij ÚÂdKª Â‹  
Ïjdhš mHš nghF«, tæ‰W tè, fhr«, Ïiu¥ò, f«kš, _¡FÚ® ghŒjš, 
të nehŒfŸ nghF«, f©Q¡F Fë®¢Áia c©L g©Q«.  
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3. 3. 7. 2 Chemical Constituents: 
Seeds 
Calcium, Phosphorous, Iron, Oxalates, Lipides & Satti Acids ,Palmitic, Steric, Oleic, 
Linoleic 
[Ramasastri Qualit Plant, 1983, 33(1), 11 Chandrasekar et al, I food sci Tech Vol 1999, 
32, 48]  
Jundishapur J Nat Pharm Prod. 2012;7(2)  
 
3. 3. 7. 3 Pharmacological Action 
In a study an antimicrobial activity of volatile oils of some spices, Con et al. 
(1998) reported that cumin had an inhibitory effect against S. aureus and M. luteus. ( J. 
Environ. Biol.  32, 251-256 (2011) 
3. 3. 8 nfhiu Cyperus rotundus,Linn. )  
Family         :      Cyperaceae 
Sans          :     Mushta  
English Name   :      Cumin seeds 
Part used   :      Seed  
 Action              :    Jt®¥Ã 
                      bt¥gK©lh¡» 
                      éa®itbgU¡»  
                      ÁWÚ®bgU¡» 
3. 3. 8. 1 General Charectristics :  
             mÂrhu« Ã¤j« md‰jhf« Ia§ 
  FÂthjŠ nrhg§ bfhoa – KÂ®thªÂ 
  ahiu¤ bjhl®ªjhY« m›tt®bfyh§Fs¤J« 
              nfhiu¡ »H§if¡ bfhL . 
Ïjdhš eë®Ru«, RutiffŸ, fê¢rš, fgnuhf« nghF«.  
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3. 3. 8. 2 Chemical Constituents:- sesquiterpenes ,Alkaloids, Alpha-cyperone, Alpha-
rotunol, Beta-cyperone, Calcium, Camphene, Copaene, Cyperene, Cyperenone, Cyperol, 
Cyperolone Cyperotundone D-copadiene, D-epoxyguaiene, D-fructose, D-glucose, Eo, 
Flavonoids, Gamma-cymene, , Kobusone, Limonene, Linoleic-acid, Linolenic-acid, 
Magnesium, Manganese, Mustakone, Myristic-acid, Oleanolic-acid, Oleanolic-acid-3-o-
neohesperidoside, Oleic-acid, P-cymol, Patchoulenone, Pectin, Rotundenol, Rotundone, 
Selinatriene, Sitosterol, Stearic-acid, Sugeonol, Sugetriol,alfa-cyperone, Beta-selinene, 
cyperotundone, sugeonol, kobusone. Alpha-  cyperone release antigonist effects for 
arachidonic acid. (WangHuikang. Foreign Medicine. TCM,1986,(4):7. )  
Anti inflammatory activity - In the model of carrageenam induced paw edema cyperus 
rotundus showed a trend to reduce the edeme while the combination of Pe + Pz (PI:20. 
64%) showed results comparable to aspirin (23. 74%). (Pupmed-indexed for 
Medline21132843) 
Antiviral Acitivity: 
 Cyperus rotundus ace found to have virucided effect against HSV. (Puppmed-
indexed for Medicine19666102) 
3. 3. 9 r®¡fiu – Sugarcane (Saccharum officinarum,Linn) 
   English Name      :   Sugarcane  
            San                       :    Iskshu, Rasalah 
            Family Name       :    Poaceae 
            Part used              :     extract from stem 
            Suvai                    :     Sweet 
            Thanmai               :     Cool 
      Pirivu           :     Sweet 
      Action               :     mGfyf‰¿ 
                             cŸsHyh‰¿ 
r®¡ifiuæ‹ Fz«: 
  mUªJ kUªÂ‰ fDkhd khf¥ 
  bghUeJ kš thªÂÃ¤j«  nghF« - tUªjU» 
  Ú¡» kÂfg¤ij Ú‰W k»œ¢Áia Í© 
  Ã¡F eUŠr®¡fiu 
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nj‹, r®¡fiu: 
 Mé dJghš mu¤ijKŸ s§»kæš 
 Öé eWŠrh«gš öJs«nj‹ - khnthk« 
 JŒa rU¡fiu JHŒéij ésh«gH« 
 Iakij nah£L m¿ 
                           (g. F. Á) 
Óå r®¡fiu: 
 Óå¢rU¡fiu¡F¤ Ôuhjh t‹RuK§ 
 jâ¡F« thj¤Â‹ T£LwÎ« VdwF« 
 thªÂbahL »Uä khwhjh é¡fYnk 
 bghªÂifia é£L¥ òu©L 
Ã¤j«, thjRu«, thªÂ, E©òG, é¡fš nghF«. bf£og£l fg¤ij 
Ïs¡F«.  
Chemical Constituents- Glucan, hemicellulose, lignin, and extractive (based on o   
ven-dry biomass) of the experimental hybrids and reference samples were 38% to 43%, 
25% to 32%, 17% to 24%, and 1. 6%to 7. 5%, respectively.  
Pharmacological Action- Conversion of glucan to glucose by commercial cellulaseswas 
increased in the samples with low lignin content. Chemical delignification further 
increased the celluloseconversion to values of more than 80%. (Masarin et al. 
Biotechnology for Biofuels 2011, 4:55) 
mDghd«: 
nj‹ 
 mDghd khŒ¥Ã‹ méœjKkhŒ¤ njh‹¿ 
 fdkhd njf ãiy fh£o¥ ÃDnk 
 aur‹ Kjšnth iuÍkh£L é¤jjhny 
 Ãur¤ Âdh‰ngh« Ãâ.  
    - nju‹ bghU£g©ò Ehš 
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nj‹: 
brŒif: 
 - nfhiHaf‰¿ 
 - gÁ¤Ôö©o 
FHªijfS¡F bfhL¡f mJ ÁWÚiu Á¿J mÂf¥gL¤JtnjhL tæ‰W¥ 
bghUkiyÍ« Fiw¡F«.  
kiynj‹  :   fgfhr« 
ÏJ kUªJfS¡F e‰Wiz kUªjhF« . 
chemical Constituents : 
 Fructose 38. 2%  
 Glucose 31. 3%  
 Sucose 1. 3% MAttose 7. 1%  
 Water 17. 2%  
 Ash 0. 2%  
 Other/Undetermined 3. 2% 
                 Its glycenic index ranges from 31 to 78 depending on the variety.  
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4. MATERIALS AND METHODS 
4. 1. Preparation of Athimaturachooranam  
 The required drugs for preparation of ATHIMATHURA CHOORNAM were 
purchased from a well reputed country shop and raw drugs are authenticated with the help 
of  Dept HOD and Herbal botanist and with Department of Gunapadam. The medicine 
was prepared in Gunapadam lab of National institute of Siddha after proper purification. 
The prepared medicine was also authenticated by the Head of the Department.  
Ingredients:  
1. Athimathuram(Glycyrrhiza glabra)    -35gm 
2. Elam(Elettaria cardomomum)        -35gm 
3. Lavangapattai(Cinnamomum verum)  -35gm 
4. Chanpaga mokku(Michelia champaga) -35gm 
5. Kottam(Costus speciosus)           -35gm 
6. Chukku(Zingiber officinale)         -35gm 
7. Nar seeragam(cuminum cyminum)    -35gm  
8. Koraikizhangu(Cyperus rotandus)     -35gm 
9. Sarkarai(sugar)                    -280gm 
 Purification & Prepartion :         
 Cardamom&korai , Lavangapattai , chanpaga mokku – dried in sun light, 
Adhimadhuram – outer layer remove the of the root and cut in to small pieces &dried it 
sun light.  Seeregam&kottam: the dus Removed and dried in sunlight , Chukku- Soaked 
in limewater filtrate and– outer layer removed. All the eight raw drugs (of equal quantity-
35gm) fried until golden brown. Then the drugs ground into fine powder form , filtered in 
fine cloth(vasthirakayam) and equal quantity of sweet candy powder added with the 
chooranam.  
 Dosage:  Verukhadi ( 1. 25 to 1. 5 grams approx) 
            750mg for 3-7 years of age, twice daily 
            1. 5gm for 8-12years of age, twice daily 
Adjuvant: honey  
duration: 7 days  
Indication: All types of Kanam, Kanasuram, Maaral suram 
Drug Storage: The trial drug ATHIMATHURACHOORANAM is stored in clean and 
dry air tight container.  
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INGRIDIENTS OF ATHIMATHURA CHOORANAM 
 
                   
                  Glycyrrhiza glabra                                   Elettaria cardomomum 
 
                  
  Cinnamom verum       Michelia chambaca 
                  
  Costus speciosus        Zingiber officinale 
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       Cuminum cyminum    Cyperus rotundus 
          
 
 
 
 
 
            Sugarcane 
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PREPARED TRIAL DRUG 
         
                                                 
 
 
 
 
 
 
TRIAL MEDICINE DISPENSING FORM 
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4. 2 Preclinical studies 
4. 2. 1 Preliminary phytochemical screening of AMC 
       
 The preliminary qualitative phytochemical screening of AMC was done by the 
method of Kolkate.  
Procedure 
Test for Calcium        : 2 ml of extract is taken in a clean test tube. To this add 2 ml of 4% 
ammonium oxide solution.  
Test for Sulphate      : 2 ml of the extract is added to 5 % barium chloride solution.  
Test for Chloride      : The extract is treated with Silver nitrate solution  
Test for carbonate    : The substance is treated with Conc. HCl.  
Test for Starch          : The extract is added with weak iodine solution  
Test for Iron (Ferric) : The extract is treated with glacial acetic acid and potassium 
ferrocyanide  
Test for Iron (Ferrous) : The extract is treated with Conc. HNO3 and ammonium 
thiocynate 
Test for phosphate      : The extract is treated with ammonium molybdate and conc. HNO3 
Test for Tannic acid  : The extract is treated with Ferric chloride  
Test for Unsaturation  : 1 ml of Potassium permanganate solution is added to the extract.   
Test for saponins        : Dilute extract+ 1ml of distilled water shake well.  
Test for sugars  :  
               Benedict method ; 5ml of Benedict solution heated gently then add 8 drops of 
diluted extract then heated in a boiling water bath.  
              Molisch test; Dilute extract+2 drops of Molisch+3ml conc. H2SO4.  
Test for steroids      :  Liberman Burchard test ; Dilute extract +2 ml acetic  
                                            anhydride+conc. H2SO4 .  
Test for amino acids     :   Dilute extract +2ml of Ninhydrin’s soln .  
Test for proteins           : Biuret method ; 1ml of dilute extract+1mlof5%CuSO4+ 
1%NaOH.  
Test for Flavanoids        :  Dilute extract+ mg bits+2drops of conc. HCl and gently heated.  
Test for phenol             :  Dilute extract+2drops of FeCl3 soln.  
Test for Tannins           :  dilute extract +2ml of 10%lead acetate add.  
Test for alkaloids          :  Mayer’s method;1ml of dilute extract + 1ml reagent.                      
                    Dragendroff’s method; 1ml of dilute extract+ 1ml of reagent.  
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4. 2. 2 Toxicity studies 
 The preclinical studies for acute toxicity was carried out in pharmacological 
laboratory in National institute of Siddha with the reference number of IAEC protocol 
no:1248/ac/09/CPCSEA and subacute toxicity studies were done in C. L. BAID MEHTA 
COLLEGE OF PHARMACY.  
4. 2. 2. 1 Drugs and chemicals 
 Standard Drugs and fine chemicals used in these experiments were obtained from 
Sigma Chemicals company, U. S. A. Other analytical grade chemicals were obtained 
from S. d. Fine Chemicals Ltd. , Mumbai.  
 4. 2. 2. 2 Experimental animals 
 Colony inbred animals strains of wistar rats of either sex weighing 200 - 250 g 
were used for the pharmacological and toxicological studies. Male guinea pig ileum(0. 
5kg)was used for the assay of antihistaminic activity of the test drug. The animals were 
kept under standard conditions 12:12 (day/night cycles) at 220C room temperature, in 
polypropylene cages. The animals were fed on standard pelleted diet 
(TANUVAS,Chennai)) and tap water ad libitum. The animals were housed for one week 
in polypropylene cages prior to the experiments to acclimatize to laboratory conditions. 
The experimental protocol was approved by the Institutional Animal Ethical Committee 
(IAEC). (IAEC/XXXV/94/CLBMCP/2012) 
 4. 2. 2. 3 Acute oral toxicity study   
 Acute oral toxicity was conducted as per the OECD guidelines (Organization of 
Economic Cooperation and Development) 423 (Acute Toxic Class Method). The acute 
toxic class method is a stepwise procedure with 3 animals of a single sex per step. 
Depending on the mortality and /or moribund status of the animals, on the average 2-4 
steps may be necessary to allow judgment on the acute toxicity of the test substance. This 
procedure results in the use of a minimal number of animals while allowing for 
acceptable data based scientific conclusion. The method uses defined doses (5, 50, 300, 
2000 mg/kg body weight) and the results allow a substance to be ranked and classified 
according to the Globally Harmonized System (GHS) for the classification of chemicals 
which cause acute toxicity. Wistar albino rats of either sex weighing 200-250 g were 
fasted overnight, but allowed water ad libitum. Since the formulation is relatively non 
 
 
62 
 
toxic in clinical practice the highest dose of 2000 mg/kg/p. o (as per OECD guidelines 
“Unclassified”) was used in the acute toxicity study. The animals were observed closely 
for behavioral toxicity, if any by using FOB (Functional observation battery).  
 4. 2. 2. 4 Repeated oral toxicity study  
 Repeated oral toxicity studies can be used to get additional information regarding 
the toxicity profile of a chemical. Repeated oral toxicity studies are defined as those 
studies where the chemical is administered to the animal for a period covering 
approximately 10% of the expected life of the animal. Usually, the dose levels are lower 
than for acute studies and allow chemicals to accumulate in the body before lethality 
occurs, if the chemical possess this ability.  
4. 2. 2. 5 Experimental procedure 
 The following experimental procedure was followed to evaluate the repeated oral 
toxicity study of AMC 
Group I : Control animals received 1%CMC, 2 ml/kg/p. o. for 14 days  
Group II : Received AMC at the dose of 450mg/kg/po in 1%CMC for 14 days 
  The dose for rats was calculated by multiplying the daily dose used in the 
clinical practice( i. e. 5000mg /day) divided by a factor 0. 018 
corresponding to the body surface area of man weighing 70kg to rat 
weighing 200g.  
               Single dose 5000mg, Daily dose 5000mg x 0. 018 =90mg for a rat 
weighing 200g. Multiply the rat dose for a rat weighing 200g x5 to get the 
dose for kg. body weight of rat (i. e. 90mg x 5=450mg/kg/po) 
 Body weight, food intake and water intake was recorded at two intervals with 
simultaneous observation for toxic manifestation and mortality, if any. At the end of 
14days treatment all the animals were sacrificed by over dosage of ether anaesthesia. 
Blood was collected and used for hematological studies. Section of liver, kidney, and 
heart were dissected out and kept in 10% formalin for histopathological studies.  
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4.2.2.6 Biochemical studies   
4.2.2.7 Aspartate aminotransferase (AST) : Aspartate aminotransferase was estimated 
using commercial AST kit (Span Diagnostics) by the method of Reitman and 
Frankel (2).  
 Alanine aminotransferase (ALT)  :  Alanine aminotransferase was estimated 
using commercial    AST kit (Span Diagnostics) by the method of Reitman and Frankel (2).  
 Alkaline phosphatase (ALP): Alkaline phosphatase was assayed using commercial 
ALP kit (Span Diagnostics) by the method of King (3).  
 Cholestrol: Cholestrol was estimated using the commercial kit(Span diagnostics) 
  Urea ,Uric acid and Creatinine: Urea,Uric acid and creatinine were assayed using 
the commercial kit (Span Diagnostics)  
4. 2. 2. 7 Haematological studies 
Erythrocyte count: Erythocyte count was estimated by Hemocytometer method 
of Ghai (4). 
Total Leukocyte Count (WBC): Total Leukocyte Count was estimated by 
Hemocytometer method of John (5).  
Haemoglobin : Haemoglobin was estimated by method of Ghai (4).  
4. 2. 2. 8 Histopathological studies  
Animals were sacrificed at the end of repeated oral toxicity and tissues were 
processed for histopathological studies.  
4. 2. 3 Anti inflammatory activity : 
 Anti inflammatory activity was evaluated in acute model of inflammation. Wistar 
rats either sex weighing 200-250g were divided into different groups with 6 animals in 
each group 
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Group-1. Control group received CMC 10ml/kg/po 
Group-2. received Carrageenan (0. 1% solution) and served as negative control 
Group-3 Received test drug(AMC) at the dose of 450mg/kg/po 
Group-4 received standard drug Diclofenac sodium(5mg/kg/po)  
Acute model 
Carrageenan induced hind paw edema  
 The carrageenan assay procedure was carried out according to the method of 
Wintar et al. (1962). Edema was induced by injecting 0. 1 ml of 1% solution of 
carrageenan in saline into the plantar aponeurosis of the left hind paw of the rats. The 
extracts, reference drug and the control vehicle (distilled water) were administered 60 min 
prior to the injection of the carrageenan. The volumes of edema of the injected and contra 
lateral paws were measured at +1, 3 and 5 hrs after induction of inflammation using a 
plethysmometer (Bhatt et al. , 1977) and percentage of anti-inflammatory activity was 
calculated.  
Chronic model 
b. Cotton pellet granuloma  
 Sterile cotton pellets (weighing 10 ± 2 mg) were implanted subcutaneously along 
the flanks of axillae and groins of wistar albino rats (Swingle and Shideman et al. , 1972). 
The extracts, reference drug and the control vehicle (distilled water) were administered as 
per protocol to rats everyday for a period of 7 days. On day + 8 the rats were sacrificed by 
cervical decapitation and cotton pellets were removed surgically, freed from extraneous 
tissue and weighed immediately for wet weight. One half of the pellets were dried in an 
incubator at 60ºC until a constant weight was obtained.  
4. 2. 4 Antipyretic activity : 
 Rats selected for the study were fasted overnight allowing water ad libitum. Initial 
rectal temperature was recorded using Hick’s clinical thermometer. Pyrexia was induced 
by subcutaneous injection of TAB vaccine 1 ml/kg body weight. Six hrs later pyrexia was 
assessed and those animals that did not show a minimum rise of 1. 5oC were rejected. The 
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animals thus found fit for the study were divided into 6 groups as described above and 
drugs were administered. Pyrexia was recorded at hourly intervals for 3 hrs after drug 
administration.  
4. 2. 5 Antihistaminic study: 
 Guinea pigs weighing (300-500 g), starved over night with water ad libitum. The 
animal was killed by a blow on the head and the neck was exsanguinated. The abdomen 
was cut open and a suitable length of the ileum (approximately 2 cm long) was placed on 
a petridish containing Tyrode solution. The composition of the Tyrode solution in mM 
was NaCl 137 mM, NaHCO3 12 mM, NaH2PO4 0. 3 mM, KCl 2. 7 mM, MgCl2 1. 0 mM, 
CaCl2 1. 0 mM and d- glucose 5. 6 mM. Experiment were performed in a 30 ml organ 
bath containing Tyrode solution maintained at 370 C under a tension of 0. 5 gm and 
gassed with air mixture (O2+CO2). Isometric contractions were recorded in a smoked 
kymograph paper with frontal writing lever. After an equilibration period of 30 min 
during which the Tyrode solution was changed intervals of 10 minutes, contractile 
responses were recorded for histamine (10 g/ml). The contact time of 30 sec recorded at 
5 min time cycle is kept for proper recording of the responses. The AMC - tissue contact 
time was 5 min before the addition of histamine. Thus, the effect of the extract on 
histamine induced contractions were recorded. The percentage inhibition of the AMC on 
contraction induced by histamine was calculated Ghosh(9).  
 4. 3 Clinical studies 
Neerkanamantham is one of the commonly encountered problem among young 
children. A protocol was prepared and submitted before IEC meeting, a copy of which is 
attached as annexure-1. After that 40 cases were selected for clinical trial from the OPD 
and IPD of Kuzhandhai Maruthuvam department National institute of Siddha.  
STUDY DESIGN & CONDUCTION OF STUDY 
 Study type      :  An open clinical trial 
 Study place    :  OPD&IPD. Of Ayothidoss pandithar hospital, 
                            National Institute of Siddha , Tambaram sanatorium, Chennai-47.  
Study period   : 12 months 
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Population and sample: 
 sample consists of patients attended the OPD of Ayothidoss Pandithar Hospital, 
National Institute of Siddha, Chennai-47  
 3-12 years age group fulfilled the inclusion criteria and exclusion criteria.  
Sample size: 40 patient 
SUBJECT SELECTION: 
As and when patients reported with symptoms of Neerkana maantham and 
fulfilled the inclusion criteria were subjected to screening test & documented using 
screening proforma.  
INCLUSION CRITERIA: 
1. Age 3 to 12 years of both sex  
2. Patients with symptoms of cough,rhinorrhoea, Intermittent fever, headache, 
rumbling noise in abdomen, diarrhea, malaise / fatigue.  
3. Willing to give specimen of blood for investigation when required.  
4. Willing to be admitted in the hospital for 7 days.  
5.  Willing to attend OPD for 7 days.  
EXCLUSION CRITERIA: 
 The patient were not eligible for admission in the clinical trial when any of the 
following was applicable.  
 Patient’s with any other serious illnesses like Tuberculosis, Jaundice, pneumonia, 
typhoid and malaria like fever, congenital heart diseases, and severe asthma.  
 Signs of severe dehydration 
 Allergic rhinitis.  
 Children with CNS disorders or EPILEPSY or history of other  factors that can  
predispose to seizures.  
 Juvenile diabetes 
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WITHDRAWAL CRITERIA: 
  Patient who felt intolerance to consume the drug & developed with adverse 
reactions during drug trial.  
 Poor patient compliance & defaulters.  
 Patient turned unwilling to continue in the course                                                                              
of clinical trial and Increase in severity of symptoms  
The trial drug “ATHIMATHURA CHOORANAM” was given continuously for 7 
days. On the 8th day patient was requested to attend the OPD for clinical assessment and it 
was recorded in the clinical assessment form and prognosis was noted . The patient’s 
informant was requested to bring back the un-consumed trial drug if any. For IP patients 
the drug was provided daily and prognosis was noted. Laboratory investigations were 
done on 0 day & 15th day of the trial were recorded. After the completion of the 
treatment, the patient was advised to visit the OPD for another 1 month for follow-up. If 
any trial patient who failed to collect the trial drug on the prescribed day but wanted to 
continue in the trial from the next day or two, he/ she was allowed, but defaulters of one 
week and more were not allowed to continue and withdrawn from the study with fresh 
case was inducted.  
DISPENSING   :   
  The ATHIMATHURACHOORANAM was given in powder form in polythene 
cover packets.  
ASSESSMENT AND TESTS : 
 Clinical assessment 
 Routine investigations 
 Specific investigations 
 Siddha assessment 
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A. CLINICAL ASSESSMENT 
 Cough 
 Intermittent Fever 
 Diarrhoea 
 Rumbling noise of the abdomen 
 Headache 
 Malaise/Fatigue 
 Blood Investigations : 
 HB  
 Total WBC Count, 
 DC 
 Total RBC count  
  ESR 
 Urine examinations:       
 Albumin 
 Sugar 
 Deposits 
Sputum test          :    AFB 
Specific investigation: Absolute eosinophil count.  
 B. SIDDHA METHOD OF ASSESSMENT : 
           Nilam, Kalam,Uyirthathukkal,Udal,thathukkal, Envagai thervugal, Neerkuri,    
Neikkuri.  
STUDY ENROLLMENT:  
 In this study, patients reported at the OPD with the clinical symptoms of 
cough,rhinorrhoea, headache, rumbling noise in abdomen, diarrhea, malaise / 
fatigue  were examined clinically for enrolling in the study based on the inclusion 
and exclusion criteria.  
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 The enrolled patients were informed about the study, trial drug, possible outcomes 
and the objectives of the study in the language and terms understandable to them.  
 After ascertaining the patients’ willingness, informed consent (Form II ) obtained 
in writing from their parents in the consent form .  
  Children who were given unique registration card with Registration number of 
the study, Address, Phone number and Doctors phone number etc. were given, can 
easily contact to the PI for any complications arise.  
 Complete clinical history, complaints and duration, examination findings-- were 
recorded in the prescribed Proforma in the history and clinical assessment forms 
separately. Screening Form- I filled up. Form III,  Form –IV and Form –V were 
used for recording the patients’ history, clinical examination of symptoms and 
signs and laboratory investigations respectively.  
 Patients were advised to take the trial drug and appropriate dietary advice was 
given according to the patients’ perfect understanding.  
DATA MANAGEMENT: 
 After enrolling the patient in the study, a separate file for each patient opened 
and all forms filed were filed. Study No. and Patient No. were entered on top of 
the file for easy identification. Whenever study patient visited OPD during the 
study period, the respective patient file was taken and necessary recordings 
were made at the assessment form or other suitable form.  
 The screening forms were filed separately  
 The Data recordings in all forms were monitored and scrutinized by HOD, Dept 
of kuzhanthai maruthuvam .  
 Data analysis was done with the help of senior research officer (statistics) of 
NIS.  
OUTCOME : 
 
 Primary     :  Assessed by the level of reduction in clinical symptoms before and after the 
treatment.  
 Secondary : 1. Reduction of AEC,  ESR.   
        2. Reversal of Neutrophil leucocytosis.  
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Adverse Effect/Serious Effect Management: 
 When the trial patient developed any adverse reaction, he/she was immedietely 
withdrawn from the trial and proper management was given in OPD of National institute 
of siddha and the same was reported to regional pharmacovigilance centre.  
ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab 
equipments were used.  
2. No other external or internal medicines were used. There was no infringement     
on the rights of patient.  
3. The data collected from the patient’s parent/guardian were kept confidentially.  
4. The patient’s parent/guardian were informed about the diagnosis, treatment 
and follow-up.  
5. Informed consent obtained from the patient’s parent/guardian explaining in the 
understandable language to his/her.  
6. After the consent of the patient’s parent/guardian (through consent form) they 
were enrolled in the study.  
7. Treatment provided free of cost.  
8. In conditions of treatment failure, adverse reactions, patients had given       
alternative treatment at the National Institute of Siddha with full care 
throughout the end.  
9. The patients with exclusion criteria not included in the trial were treated as 
regular cases in the OPD of Ayothidass Pandithar Hospital.  
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5. OBSERVATIONS AND RESULTS 
5. 1. Preliminary phytochemical screening 
      Preliminary Qualitative analysis of drug AMC 
Observation Inference 
No white precipitate is formed Absence of calcium  
No white precipitate is formed  Absence of Sulphate  
 White precipitate is formed Presence of Chloride 
No effervescence is formed  Absence of carbonate 
No blue colour is formed Absence of starch  
No blue colour is formed Absence of Ferric iron 
Blood red colour is formed Presence of Ferrous iron 
Yellow precipitate is formed Presence of phosphate 
Black precipitate is formed Presence of Tannic acid 
Does not get decolourised  Absence of unsaturated 
compound 
No Froth formation Absence of saponins 
No colour change occured 
 No Reddish violet zones 
appeared 
Indicates the Absence of sugar.  
Absence of carbohydrate 
No Formation of red colour  Absence of steroids 
Formation of violet colour Presence of amino acids 
Formation of deep blue colour Presence of proteins 
Formation of pink colour Presence of Flavanoids 
 No green colour is formed Absence of phenols 
White precipitate formed Presence of tannins 
Appears cream colour 
precipitate 
Appears orange colour 
precipitate 
 
Presence of alkaloids 
 
Presence of alkaloids 
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5. 2 Preclinical studies 
Acute oral toxicity study 
AMC at the dose of 2000mg/kg/po did not exhibit any mortality in rats. As per 
OECD 423 guidelines the dose is said to be “Unclassified” under the toxicity scale. 
Hence further study with higher doses was not executed 
Repeated oral toxicity  
Test drug AMC at the dose of 450mg/kg/po when administered orally for 14 days 
in rats did not exhibit toxicity in haematopoeitic system,liver and kidney (Tables 2, and 3) 
 Histopathological study 
AMC at the dose of 450 mg/kg/po daily administered for 14ys did not show 
evidence of  pathological lesions in the tissues teste 
Groups Hb (gm/100ml) RBC 
(millions/cu. 
mm) 
WBC (cells/cu. 
mm) 
Differential leucocyte count (%) 
Lympho 
cytes 
Mono 
Cytes 
Granulo 
cytes 
Normal 14. 0  0. 354 5. 9 1  0. 665  5785  9. 434 75. 06  3. 829  6. 30  1. 904 17. 70  5. 627 
AMC(450mg/k
g/p. o) 
14. 88  0. 710 ns 5. 89  0. 737 ns 5886. 66  3. 343ns 76. 67  3. 382 ns 6. 06  1. 7 ns  17. 66  1. 474 ns 
 
n=6; Values are expressed as mean  S. D followed by Students Paired ‘T’ Test 
ns – non significant when compared to control groups  
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Effect of Siddha formulation (AMC) on Biochemical markers of liver and kidney 
after 14 days repeated oral dosing (450mg/kg/po) in rats  
 
Groups AST 
(IU/L) 
ALT 
(IU/L) 
Cholestrol 
(mg/dl) 
Urea 
(mg/100ml) 
Uric acid 
(mg/ 100ml) 
Normal 69. 480. 273  30. 40  0. 831 44209  0. 797 24. 72  0. 537 2. 01 0. 650 
AMC(450mg/kg/p. o) 72. 655. 952 ns 33. 61  6. 267 ns 41. 09  0. 627ns 23. 90  1. 59 ns 2. 47  0. 735 ns 
 
N=6; Values are expressed as mean  S. D followed by Students Paired ‘T’ Test 
Ns – non significant when compared to control groups  
Antiinflammatory studies  
AMC at the dose of 450 mg/kg/p. o showed significant anti-inflammatory activity 
in carrageenan induced hind paw edema (acute inflammation model)and Cottton pellet 
granuloma methods (Chronic model) in rats. The results of present study were 
comparable to that of the standard NSAID Diclofenac sodium (5 mg/kg/p. o)  
Effect of AMC on Carrageenan induced hind paw edema in rats 
Treatment 0min 30min 60min 120min 240min 
Control-Group-1 
 
0. 871±0. 16 0. 890±0. 072 0. 852±0. 0. 
117 
0. 901±0. 083 0. 872±0. 764 
Edematous control-
Group-2 
0. 873±. 0. 20 0. 967±0. 
102**a 
1. 084±0. 
021***a 
1. 123±0. 
310***a 
1. 007±0. 764 
Test(AMC)-Group-3 0. 8710. 011 0. 9310. 083 0. 9100. 
002**b 
0. 9380. 
09***b 
0. 8820. 
078**b 
Standard (Dic. 
Sodium 5 
mg/kg/po)Group-4 
0. 8930. 
013ns 
0. 8960. 
067*b 
1. 120. 072**b 0. 9660. 
041***b 
0. 8760. 
028**b 
 
n=6; Values are expressed as mean  S. E Values are compared with control and analyzed 
by Student’s ‘t’ test.  
**P<0. 01,***p<0. 001 as compared with respective control.  
a:group 1 vs group 2 
b: group 2 vs groups 3 and 4 
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Anti-inflammatory activity of (AMC) in Cotton Pellet Granuloma 
 
Groups Cotton pellet Granuloma method 
Dry Weight (mg) 
Control 107. 97  9. 42 
Test(MVM) 73. 08  61. 30** 
Standard (Dic. Sodium  
5 mg/kg/po) 
66. 31  3. 12** 
 
 
n=6; Values are expressed as mean  S. E Significance was assessed by paired Student’s 
‘t’ test 
*P<0. 05 **p<. 01as compared with that of control.  
ns – non significant when compared to control groups  
 
Antipyretic activity of (AMC) in rats 
 
Groups Rectal temperature (0C) 
0 min 30 min 60 min 120 min 240 min 
ControlGroup-1 34. 
902. 18 
37. 201. 24 38. 170. 34 37. 3 01. 08 36. 760. 78 
pyretic control 
Group-2 
35. 
01±0. 12 
37. 08±0. 14*a 39. 21±0. 
05**a 
39. 90±1. 
01***a 
39. 87±0. 
94***a 
Test (AMC) 
Group-3 
35. 
130. 20 
36. 800. 50 35. 940. 
41***b 
36. 02 
0. 05***b 
36. 310. 30**b 
Standard (Dic. 
Sodium  
5 mg/kg/po)Group-4 
35. 
600. 98 
ns 
36. 880. 95 
Ns 
35. 990. 
61***b 
35. 750. 20***b 36. 510. 72**b 
 
n=6, Values are expressed as mean  S. E using Student’s paired ‘t’ test.  
*P<0. 05**p<0. 01,***p<0. 001 as compared with that of control.  
a Comparison between group-1 vs group-2 
b::omparisonbetween group -2 vs Groups 3 and 4 
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Antihistaminic effect 
 
AMC exhibited antihistaminic effect in the contraction of g. pig ileum elicited 
with histamine. A dose dependent inhibition of contraction was observed with AMC and 
100% inhibition was achieved with a concentration of 32mg/ml dose against 8 microgram 
of Histamine(Table-7) 
 
Effect of the AMC on histamine induced 
Contractions of guinea pig ileum 
S.  
No 
Treatment Mean 
contraction 
(mm) 
% inhibition of 
histamine 
Histamine 
( g/ml) AMC (mg/ml) 
1 8. 0 Control 43 ± 1. 52 0 
2 8. 0 1 32 ± 2. 08 25. 58* 
3 8. 0 2 24 ± 1. 15 44. 18** 
4 8. 0 4 18 ± 1. 00 58. 13*** 
5 8. 0 8 11 ± 1. 00 74. 41*** 
6 8. 0 16 5 ± 1. 00 88. 37*** 
7 8. 0 32 0 ± 0 100* 
 
Values are mean ±SEM of triplicates.  
*p<0. 05**p<0. 01 ***p<0. 001 Values are against control 
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5. 3 Clinical Studies 
 For the clinical study 40 cases were selected and treated, in which 30 cases were 
treated in OPD and 10 cases were treated in IPD of National Institute of Siddha. Results 
were observed with respect to the following criteria 
Results were observed with respect to the following criteria: 
1. Age 
2. Sex 
3. Parent’s Socio Economic Status 
4. Diet 
5. Religion 
6. Paruvakaalam 
7. Uyir thathukkal 
8. Ezhu udal kattugal 
9. Envagaithervugal 
10. Neikuri 
11. Cllinical features 
12. Haemotological Profile 
13. Biochemical Analysis 
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Table 1 
Distributions of patients with Neerkanamantham according to Age Distribution 
 
Age No of cases Percentage% 
 3-7 years 22 55 
8-12 years 18 45 
 
Neerkanamantham according to Age Distribution 
 
 
Inference: 
 Out of 40 patients, 55% of cases were 3-7 years, 45% were 8-12 years.  
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Table 2 
 
Distributions of patients with Neerkanamantham according to  
Gender Distribution 
 
Gender No of cases Percentage% 
Male child 26 65 
Female child 14 35 
Total 40 100 
 
26
65%
14
35%
0
10
20
30
40
50
60
70
Male child Female child
No of cases
Percentage%
 
 
Inference: 
Out of 40 patients 65% were male children and 35% were female children  (Table 2).  
So there is no marked difference in sex distribution and this disease can affect 
either sex.  
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Table 3 
Distributions of patients Neerkanamantham with according to 
 parent’s Socio Economic Status 
 Socio Economic Status    No of Patients       Percentage(%) 
Lower Income Groups           19         47. 5 
 Middle Income Group           14         35 
 High Income Groups           7         17. 5 
Total           40         100 
        
Lower
Income
Groups
 Middle
Income
Group
 High
Income
Groups
Total
     No of  Patients
           Percentage(%)
47.5
35
17.5
100
19
14
7
40
0
10
20
30
40
50
60
70
80
90
100
     No of  Patients
           Percentage(%)
 
 
Inference:  
 About 47. 5% patients were under Lower Income Group, 35% patients were under 
Middle Income Group and 17. 5% patients were under High Income Group. The highest 
incidence occurred in lower Income Group.  
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Table 4 
Distributions of patients with Neerkanamantham according to Diet 
Diet No of Cases Percentage% 
Vegetarian 7 17. 5 
Non vegetarian 33 82. 5 
Total 40 100 
 
 
DIET 
 
 
Inference:  
 According to diet, high incidence of cases (82. 5%) was noted in non vegetarian 
and in vegetarian 17. 5% cases were noted. (Table 4) 
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Table 5 
Distributions of patients with Neerkanamantham according to Religion 
Religion No of Cases Percentage% 
Hindu 36 90 
Christians 1 2. 5 
Muslims 3 7. 5 
Total 40 100 
 
36
90 %
1
2.5 %
3 7.5 %
0
10
20
30
40
50
60
70
80
90
Hindu Christians musilms
NO OF CASES
PERCENTAGE
 
 
Inference:  
 According to Relegion, high incidence of cases (90%) was noted in Hindu. in 
Christian was2. 5 %, and in Musilims- 7. 5% cases were noted. (Table 5) 
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Table 6 
Distributions of patients with Neerkanamantham according to Paruva Kalam  
(Seasonal Variation) 
Paruva kalam No. of Cases Percentage% 
Karkalam 12 30 
Koothirkalam 6 15 
Munpani kalam 0 0 
Pinpanikalam 0 0 
Elavenil kalam 0 0 
Muthuvenil kalam 22 55 
Total  40 100 
 
 
 
Inference:According to paruva kaalam, high incidence of cases (55%) were noted in 
Muthuvenilrkaalam. In Karkalam- 30% In Koothirkalam 15%, cases were noted.  
(Table 6) 
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Table 7a.  
Distributions of patients with Neerkanamantham according to Vali (Vatham) 
Types of vatham No of Cases Percentage (%) 
Pranan 40 100 
Abanan 14 35 
Viyanan 0 0 
Uthanan 40 100 
Samanan 24 60 
Naagan 0 0 
Koorman 0 0 
Kirukaran 40 100 
Devathathan 25 60 
Dhananjeyan - - 
 
 
 
 
 
 
 
 
 
 
 
 
Inference: 
 `According to vadham, derangement of Pranan, Uthanan, kirukaran was 100%, 
Samanan  was deranged in 60% Abanan was deranged in 35%, Devathathan was 
deranged in 60%(Table7a).  
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Table 7. b 
Distributions of patients with Neerkanamantham according to Azhal (Pitham) 
Types Of Azhal No. of Patients Percentage (%) 
Analagam (Aakanal)  24 60 
Ranjagam (Vannaerri) 8 20 
Sathagam (Aatralangi ) - - 
Alosagam (Nokkanal) - - 
Prasagam (Oollolithee) 8 20 
 
 
 
Inference:  
According to Pitham, derangement of Analagam was deranged in 70%, Ranjekam, 
Prasagam was deranged in 20% (Table7b).  
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Table 7. c 
Distributions of patients with Neerkanamantham according to Iyam (kabam) 
 
Types of Iyyam No. of Patients Percentage (%) 
Avalambagam (Alliyyam)         40         100 
Klethagam (Neerpiyyam)         24          60 
Pothagam (Suvaikanaiyyam) - - 
Tharpagam (Niraivaiyyam) - - 
Santhigam (Oondriyyam) - - 
 
 
 
Inference:  
 `According to Kabam, derangement of Avalambagam was 100%, Kelathagam was 
deranged in 60% (Table7c).  
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Table 8 
Distributions of patients with Neerkanamantham according to Ezhu udal 
thaathukkal 
Udal thaathukkal No of Patients Percentage (%) 
Saaram  40 100 
Senneer  8 20 
Oon  0 0 
Kozhuppu 0 0 
Enbu   0 0 
Moolai    0 0 
Sukkilam 0 0 
Suronitham 0 0 
 
 
 
Inference:  
Saram was affected in 100% of cases, Senneer was affected in 20% of cases 
(Table8).  
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Table - 9 
Distributions of patients with Neerkanamantham according to Envagai thervugal 
Ennvagai thervukal No of cases Percentage 
Naadi: Vathapitham     
 Pithavatham
 Pithakabam 
28 
7 
5 
70 
17. 5 
12. 5 
Sparisam 21 52. 5 
Naa 0 0 
Niram 0 0 
Mozhi 0 0 
Vizhi 0 0 
Malam 5 12. 5 
Moothiram 0 0 
 
 
 
Inference: 
In Naadi, Vathapitham was observed in 70% of cases, Pithavatham was observed 
in 17. 5% of cases, Pithakabam was observed in 12. 5% of cases. Out of cases, low grade 
fever was observed in 52. 5% of cases. Malam was observed in 12. 5% of cases. (Table 9) 
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Table - 10 
Distributions of patients with Neerkanamantham according to Neikuri 
 
Neikuri No. of Patients Percentage (%) 
Vaatham 20 50 
Pitham 13 32. 5 
Kabam 7 17. 5 
 
 
 
Inference 
According to Neikuri, Vatha neer was observed in 50% of cases, pitha neer was 
observed in 32. 5% of cases, Kaba neer was observed in 17. 5% of cases (Table10).  
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Table - 11 
Distributions of patients with Neerkanamantham according to the clinical features 
Clinical 
Features 
No of patients 
observed Before 
treatment 
Percentage 
(%) 
No of patients 
observed 
after treatment 
Percentage 
(%) 
Cough 40 100 8 20 
Rhinorrhoea 36 90 0 0 
Intermittent fever 21 52. 5 0 0 
Headache 13 32. 5 4 10 
 Rumbling noise in 
abdomen 10 25 2 5 
Diarrhoea 5 12. 5 0 0 
malaise / fatigue 24 60 6 15 
 
 
Inference 
Among the 40 cases, 100% of the patients had cough, 90% had Rhinnorrhoea, 60. 
% had malaise/ fatigue, 52. 5% had Intermittent fever 32.5% had headache, Rumbling 
noise in stomach had 25%, 12. 5% of patients had diarrhoea of cases at the base the 
treatment. At the end of the treatment, Cough in 20% of cases, Malaise/fatigue in 15% of 
cases , headache in 10% of cases, rumbling noise in abdomen in 5% of cases, 
Rhinorrhoea, Intermitent fever , Diarrhoea 0% of cases were noted. (Table11).  
12. Laboratory investigations 
Most of cases were had increased WBC COUNT , EOSINOPHIL COUNT and 
AEC LEVEL . Sputum for AFB negative for all cases.  
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Table - 12 
Result 
Result No. of Patients Percentage (%) 
Good 31 77. 5 
Moderate 5 12. 5 
Mild 4 10 
Total 40 100 
   
77.5%
12.5%
10%
Results
Good Moderate mild
 
 
 
 
Inference:Out of the 40 cases, the signs and symptoms were good in 77. 5% of cases, 
moderate in 12. 5% of cases, mild in 10%. These results were based on the clinical 
improvement.  
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13. STATISTICAL ANALYSIS 
All collected data were entered into computer using MS Excel software. The 
data entry was cross-checked manually with CRF. The data was analyzed using SPSS 
version 18. 0 software. The probability value 0. 05 was taken as significant level. 
Paired‘t’ test was employed to determine the significance of blood sugar at before and 
after treatment.  
Mean ±Standard deviation of clinical features (CF) of Neerkanamantham at - 
Before and after treatment  
CF – Before treatment  5.56 ± 1.095  t = 24.615, p <0. 001  
 Significant 
CF – After treatment  0.33 ± .662 
 
The average clinical features of Neerkanamantham at the start of treatment 
and after the treatment were 5.56 and 0. 33 respectively.  
There is statistically significant difference between before and after treatment 
of clinical features of Neerkanamantham (p<0. 001).  
Mean ±Standard deviation of AEC - Before and after treatment  
AEC Before treatment  329.85± 177. 448  t = 10.855, p <0. 001  
 Significant 
AEC After treatment 150.98± 100.041 
 
The average AEC at the start of treatment and after the treatment were 
329.85and 150. 98 respectively.  
 There is statistically significant difference between before and after treatment 
of AEC (p<0. 001).  
Mean ±Standard deviation of Hemoglobin (Hb) before and After treatment  
 Hb – Before treatment  12.220 ± 1.6337 t = -2.648 p <0. 012  
Significant 
Hb - After treatment 12.640 ±1.7104 
The average Haemoglobin at the start of treatment and after the treatment was 
12.220and 12.640 respectively. There is statistically significant difference between 
before and after treatment of Hemoglobin (p<0. 012).  
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6. DISCUSSION 
“Neerkanamantham” is a most common infectious disease of respiratory 
tract of childhood. In our Siddha texts, Neerkanamantham is one of the type among the 
24 kanams. It is more or less resembles common cold in modern literature.Thedisease 
is characterized by cough , rhinnoroea , intermittent fever , rumbing noise in stomach, 
diarrhoea, headache, general myalgia.In the present study, forty cases were treated in 
the outpatient and inpatient department, according to clinical features mentioned in 
textbook of Balavagadam.  
The diagnosis was carried out in the basis of siddha methods and recorded in 
selection proforma with the help of laboratory investigations.  
The diagnosis was confirmed and the patients were  treated with the trial drug 
“Athimathura chooranam” and clearly observed.  
This study clearly describes the effect of “Athimathura chooranam” in 
relieving the symptoms of Neerkanamantham.  The discussion was made out on the 
basis obtianed results and observation. 
 Age: 
 In the present study, maximum number of patients were in the age group of 3-
7 years (55%) and 8-12 years (45%).  
 Sex:  
Maximum number of patients (65%) was male.  
 Seasonal Variation:  
Rainy season was the triggering factor in aggravation of the disease 
Neerkanamantham and was observed in 55% of patients in Muthuvenilkalam. kanam 
is highly influenced by seasonal variations.  
 Vali (Vatham) 
Due to the derangement of different vatha the following symptoms occur. 
Pranan, Uthanan was affected in 100% cases and causes cough. Abanan was affected 
in35 % and causes diarrhoea. Samanan was affected in 60% cases . Kirukaran was 
affected in 100% and causes cough and Devathathan was affected in affected in 60% 
cases and causes malaise.  
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 Azhal (Pitham) 
Due to the derangement of Pitham the following symptoms occur. Analagam 
was affected 60% and causes poor appetite. Ranjakam was affected 20% and causes 
reduced haemoglobin. Pirasakam was affected 20% and causes pallor of skin.  
 Iyyam (Kabam) 
Deranged Avalambagam was affected 100% and causes cough Klethagam was 
affected 60% and causes poor appetite.   
 Ezhu udarkattugal 
In Ezhu udal kattukal, Saram was affected 100% and causes malaise, fatigue. , 
Seneer was affected in 20%.  
 Envagai thervugal 
 According to this study, 
Sparisam was affected in 52. 5% 0f cases (raised temperature) 
Malam was affected in 12. 5% of cases.  
 Naadi: 
 Vathapitham was observed in 70 % of cases,  
Pithavatham was observed in 17. 5% of cases,  
Pithakabam was observed in 12. 5% of cases.  
According to naadi, high Distribution observed in vali Azhal, Azhal vali and 
Azhal iyyam naadi. In siddha literature, the character of vali Azhal is mainly 
constipation, poor appetite, abdominal pain, indigestion and nausea.  
 Neerkuri 
Regardin moothiram, neerkuri showed straw coloured urine in all cases.  
 Neikuri 
In the present study, 50% of patient had vatha neikuri, 32. 5% was observed as 
pitha neikuri and 17. 5% was observed as kaba neikuri. According to this neikuri, 
vadham was dominately affected.  
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 Distribution according to clinical presentation 
Of the 40 patients of kanam in the present clinical trial,  
All (100%) had Cough 
Rhinorrhoea in 90%  
Rumbling noise in stomach was reported in 25%,  
Headache 32. 5%,  
Intermitent fever in 52. 5%,  
Diarrhoea was seen in12. 5%.  
Malaise/ fatigue in 60% 
 The clinical improvements were accurately noted and further follow up was 
made in outpatient department.  
 Laboratory investigations 
Most of cases were had increased  WBC and AEC and Sputum for AFB 
negative for all cases.  
 Biochemical analysis 
The Bio chemical analysis of trial medicines showed the presence of Calcium 
and Ferrous Iron, Starch , Tannins, Phosphate, Alkaloids, Flavonoids, protein, 
Aminoacid, sterols, phenols.  
 Ferrous iron is more soluble and therefore more readily absorbed. Iron helps 
in increasing the haemoglobin level of blood. Calcium is essential for growth, as it 
plays an important role in the formation of bones and development of teeth.  
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7. SUMMARY 
Patients attending the OPD, IPD of NIS having the complaints of  
Neerkanamantham diagnosed clinically and the patients were observed for clinical 
diagnosis, laboratory diagnosis.  
Classical symptoms of Neerkanamantham with emphasis to symptoms of 
common cold like cough, rhinnoroea , intermittent fever , rumbling noise instomach, 
diarrhoea, headache,  malaise/ fatigue .  
Clinical diagnosis of Neerkanamantham was done on the basis of clinical 
features described in Balavagadam text.  
Laboratory diagnosis was done by modern methods of examinations.  
Diagnosis had been based on the specially prepared proforma, including all 
clinical signs and symptoms of the disease, in which detailed history had been taken.  
The signs, symptoms, and etiopathogenesis of common cold explained in 
modern diagnosis have lot of similarities with the disease  entity Neerkanamantham.  
The medicine chosen for clinical treatment and management of 
Neerkanamantham is & Athimathura chooranam internally two times in a day for 7 
days.  
All the patients were kept under strict dietary control during the treatment. The 
observation on effect of therapy was encouraging.  
The clinical efficacy of the drug was analyzed statistically on all the symptoms 
mentioned in the assessment criteria. The observation made during the clinical study 
showed that the trial drug Athimathura chooranam was clinically effective.  
In Bio chemical analysis, the trial medicine Athimathura chooranam had 
Calcium and Ferrous Iron, Starch , Tannins, Phosphate, Alkaloids, Flavonoids, 
protein, Aminoacid, sterols, phenols.  
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8.  CONCLUSION 
 All the forty patients of Neerkanamantham were treated with Athimathura 
chooranam internally two times in a day.  
The ingredients of Athimathura chooranam are feasible and useful; these 
compounds may serve as potentially useful drug for Neerkanamantham at a lower 
cost.  
The medicine has many properties to control the signs and symptoms of 
Neerkanamantham. During the course of treatment, no adverse interactions were 
observed.  
Clinical results were found to be significant good improvement was found in 
77. 5% of cases, moderate in 12. 5% of cases, mild in 10% of cases.  
Because of the efficient results clinically, the study may be carried over to 
further researches and it may motivate the upcoming generation to manage the disease 
Neerkanamantham through the siddha medicine and also this study throw new glitters 
for the Siddha Medicine.  
So the present clinical study has established that Athimathura chooranam is 
having good result in reducing the majority of symptoms of the Neerkanamantham.  
The trial drug Athimathura chooranam is denoted in Balavagadam Text as a 
common effective drug for all types of kanam and through this trial, the effectiveness in 
Neerkanamantham was confirmed and re-established  
 
 
 
 
 
 
 
 
 
99 
 
ANNEXURE -I 
PROFORMA 
 
     NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A STUDY ON NEERKANAMAANTHAM IN CHILDREN 
 PATIENT SCREENING FORM  
1. S1. No:                2. OP/IP No:              3. BED. No:  
 4.  NAME:               5. AGE:                  6. GENDER:  
7. DATE:                 8. INFORMANT:         9. CONTACT. NO: 
  
10. DATE OF ENROLLMENT:                  11. DATE OF COMPLETION: 
  
12:RELIABLITY: 
 
a) INCLUSION CRITERIA 
  Age: between 3-12 years            YES     NO 
     Cough     
    Rhinorrhoea       
    Intermittent fever            
    Headache        
    Rumbling noise in abdomen     
    Diarrhoea         
       Malaise/fatigue 
 
      Willing to give specimen of blood for investigation when required.  
      Willing to be admitted in the hospital for 7 days  
      Willing to attend OPD for 7 days 
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 b) EXCLUSION CRITERIA: 
A patient is not eligible for admission to the trial if any following is applicable.  
Tuberculosis 
Jaundice  
Pneumonia 
Typhoid and malaria like fever 
Congenital heart diseases 
Severe asthma 
Signs of severe dehydration 
Allergic rhinitis 
Children with CNS disorders or EPILEPSY or history of other  factors that can  
predispose to seizures.  
Juvenile diabetes 
   
c) WITHDRAWAL CRITERIA: 
Intolerance to consume the drug & development of adverse reactions  
during drug trial.  
Poor patient compliance & defaulters.  
Patient turned unwilling to continue in the course                        
of clinical trial and Increase in severity of symptoms 
 
 
  ADMITTED TO TRIAL :           1. YES               2. NO 
 
        If yes, S. No:                1. IP             2. OP 
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   NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
          A STUDY ON NEERKANAMAANTHAM [COMMON COLD] IN CHILDREN 
CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent.                                                  Signature………………….                         
Date………………………                                                     Name…………………… 
 
CONSENT OF INFORMANT 
 
I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up including 
the laboratory investigations to be performed to monitor and safeguard my 
Son/Daughter body functions.  
I am aware of my right to opt out of the trial at any time during the course of 
the trial without having to give the reasons for doing so.  
I, exercising my free power of choice, hereby give my consent to be included 
as a subject in the clinical trial of ‘ATHIMATHURA CHOORANAM’ for the 
treatment of ‘NEERKANAMAANTHAM’ [COMMON COLD].  
                                                                               
 
Signature………………… 
 
Date:        Name:…………………… 
 
Place:        Relationship:…………….  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A STUDY ON NEERKANAMAANTHAM [COMMON COLD] IN CHILDREN 
        CASE REPORT FORM 
 
1. S. No :               2. OP/IP No:  3. Bed. No: 
 
4. Name  :   _______________________ 5. Age (Yr)  : 
 
6. Gender  : MC   FC 
 
7. Father’s Name      :  
 
9. Father’s Occupation  : 
  
10. Mother’s Name     : 
 
11. Religion : 
 
12. Monthly /Annual Income :  
 
13. Socio Economical Level  : 
 
14. Informant   :  Mother Father  Guardian     --------------------- 
 
    
15. Postal Address   : 
  
    
     
16. Complaints and duration  :  
 
 
 
 
17. History of present illness  :  
 
 
 
 
18. Past History    :    
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19. Family History :   
 Any H/O of Hereditary/ Familial disease: Yes                  No 
If yes, details-------- 
 Positive Familial H/O PT           Yes      No 
If yes, details_______ 
21. Personal Habits:     
      
      1. Picca :         1. Yes                    2.  No  
 
      2. Bed wetting:  1. Yes                   2.   No  
   
      3. Thumb sucking  1. Yes                   2.  No  
 
      4. Nail bitting           1. Yes                   2.  No 
 
 
22. Food Habits:       1. Veg     2.   Non Veg         3.  Mixed   
 
 
23. Immunization History:    
   Immunization done upto age:  Yes          No 
(According to National Immunization Schedule) 
If not, Details_______ 
Any special vaccine given Hep. B  HIB  Typhoid  
 
 
GENERAL EXAMINATION: 
 
  
 VITAL SIGNS: 
 
Pulse rate  ______ /min 
Heart rate: _______/min 
Respiratory Rate______ /min  
Temperature: _______Degree F 
Height: ______cm 
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Weight: ______ kg   
Pallor:   Present            Absent 
Jaundice: Present             Absent 
Clubbing: Present             Absent 
Cyanosis: Present             Absent 
      Pedal Edema:  present                 Absent 
      Lymphadenopathy:Present          Absent 
 
EXAMINATION OF RESPIRATORY SYSTEM: 
 
a)   Inspection: 
Shape –    :Normal            Barrel-Shaped                      Pigeon chest 
Shoulder Drooping:  Absent         Present 
Intercostals spaces:  Normal        Bulge         Indrawing 
Spine           :  Normal        Kyphosis        Scoliosis 
Supraclavicular fossae: Normal         Flattening          Hollowing 
Position of mediastinum: 
 Traile’s sign:  Present                       Absent 
 Apical impulse-------- 
b) Palpation: 
Tenderness    Yes No 
       If yes___________ 
Tactile vocal Fremitus: Normal and equal 
Increased 
 Decreased 
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C) Percussion:     
Percussion on all over area:  Normal           
Hyper resonance                               
Dullness 
D)  Auscultation: 
Intensity of breath sounds: Normal/decreased/increased __________ 
Adventitious sounds 
 Wheeze   Crepitations  Rub    None of above 
Vocal resonance: Normal/ Increased/ Decreased ______________ 
Other systems:   Normal  Affected 
Cardio vascular system: 
Gastro intestinal system: 
Musculo skeletal system:  
Central nervous system: 
Endocrine system:  
 
26. CLINICAL ASSESSMENT: 
         Yes No   
Cough 
 
Intermittent Fever 
 
Diarrhoea 
 
Rumbling noise of the abdomen 
 
Headache 
 
Malaise/Fatigue 
 
 Rhinorrhoea 
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SPECIAL EXAMINATION: 
 
NILAM:  
 
         Kurinji    Mullai   Marutham 
 
         Neithal    Paalai     
 
KAALAM:    
 
Kaarkalam      Koothirkaalam 
 
   Munpanikaalam     Pinpanikaalam 
 
         Illavenirkaalam                  Muthuvenirkaalam 
 
 
 YAAKAI: 
 Vatham     Vatha pitham          VathaKabam 
 
     Pitham     Pitha vatham            PithaKabam 
 
     Kabam     Kaba vatham             Kabapitham 
 
 GUNAM:   
 
      Sathuvam     Rasatham      Thamasam  
  
PORI PULANGAL: 
       Normal      Affected 
Mei                                              _______  _______                                            
  
Vaai                                             _______  _______  
      
Kan                                             _______  _______  
 
Mooku                                           _______  _______   
  
 Sevi                                             _______  _______  
 
KANMENDHIRIUM / KANMAVIDAYAM 
                         Normal  Affected  
 
  KANMENDHIRIUM / KANMAVIDAYAM 
 
 
   Kai                                                                                       ______ _______   
                
  Kaal               __     _____  _______  
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  Vaai          _______  _______ 
        
  Eruvai         _______  _______ 
         
  Karuvai         _______  _______  
 
 
UYIR THATHUKKAL 
 
a)VATHAM :   
                          Normal  Affected 
 
  Pranan             ______________ 
  
  Abanan              ______________ 
  
  Viyanan        _______________ 
 
  Uthanan        _______________ 
 
  Samanan        _______________ 
 
  Nagan        _______________ 
 
  Koorman        _______________ 
 
  Kirukaran        _______________ 
 
  Devathathan       _______________ 
 
  Dhananjeyan       _______________ 
 
  
b)PITHAM    Normal    Affected  
 
  Analam        _______________ 
 
  Ranjagam        _______________ 
 
  Saathagam        _______________ 
 
  Alosagam        _______________ 
 
 Prasagam        _______________ 
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c)KABAM     Normal    Affected 
 
1. Avalambagam       _______________ 
 
2. Kilethagam             ______________   
 
3. Pothagam        _______________ 
 
4. Tharpagam             _______________ 
 
5. Santhigam        _______________ 
 
 
UDAL THATHUKKAL   Normal     Affected 
 
  Saaram        _______________ 
 
  Senneer        _______________ 
 
  Oon        __     ______________ 
 
  Kozhuppu        _______________ 
 
  Enbu        _______________ 
 
  Moolai        _______________ 
 
  Sukilam / Suronitham      _______________ 
 
 
ENVAGAI THERVUGAL 
      Normal   Affected 
 
   Naa : 1. Colour       _______________ 
 
       2. Character                                          ______________ 
  
       3. Sensory function                                    ______________ 
 
  Niram        _______________ 
 
  Mozhi        _______________ 
 
  
 
 Vizhi : 1. Colour       _______________ 
 
         2. Character                                                                               _______________ 
  
        3. Sensory function                                                                     _______________ 
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   Sparisam        _______________ 
 
 
  Malam:    Normal   Affected 
 
     1. Niram              ____________ 
 
     2. Nurai                                                                                 ____________ 
        
     3. Elagal/Erugal                        ____________ 
        
     4. Murai             _____________ 
 
  Moothiram: 
 
  Neer kuri    Normal    Affected 
 
    1. Niram        _______________ 
 
    2. Edai        _______________ 
 
    3. Manam        _______________ 
 
    4. Nurai        _______________ 
 
    5. Enjal        _______________ 
 
    6. Nei kuri:         
     
1. Vatham  2. Pitham  3. Kabam   4. Thontham  
 
  Naadi-1)Thani naadi: 
 
       1. Vatham   
 
       2. Pitham   
 
      3. Kabam  
   
       2)Thontha Naadi: 
            
             1. Vatha pitham 
 
         2. Pitha vatham 
               
   3. Pitha kabam     
 
             4. Kaba pitham 
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         3)Mukkutra Naadi: 
               
        
  4)Thoda Naadi: 
 
             1. Vatha kabam 
 
             2. Kaba vatham 
 
      
 Diagnosis: 
 
DRUGS ISSUED : 
Date    : 
Station   : 
     Signature of principal investigator
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A STUDY ON NEERKANAMAANTHAM [COMMON COLD] IN CHILDREN 
LABORATORY INVESTIGATIONS 
1. SI. No:                       2. OP/IP No:              3. BED. No:  
 4.  NAME:                       5. AGE:                 6. GENDER:  
 7.  DATE:                       8. INFORMANT:          9. CONTACT. NO: 
      10. DATE OF ENROLMENT:            11. DATE OF COMPLETION: 
Date:     Lecturer                HOD 
 
Urine 
Investigation 
Before TMT 
Date: 
After TMT  
Date: 
Albumin   
Sugar   
Deposits   
 
Date:            Signature of principal investigator
Routine Blood Investigations Normal Values 
Before 
Treatment  
Date: 
After 
Treatment  
Date: 
Hb ( gms%)  11. 5 – 14. 5    
T. RBC (milli /cu. mm)     4-4. 9   
 
ESR (mm) 
½ hr.  0- 4   
1 hr.      0-13   
T. WBC (milli /cu. mm) 5000-14500   
Differential Count (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
Absolute Eosinophil 
Count 440 cells/cu m. m   
Sputum for AFB    
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NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
POST GRADUATE DEPARTMENT OF KUZHANDHAI 
MARUTHUVAM 
       A STUDY ON NEERKANAMAANTHAM [COMMON COLD] IN 
CHILDREN 
CLINICAL ASSESMENT FORM 
 
1. SI. No:    2. OP/IP No:             3. BED. No:  
    4.  NAME:                     5. AGE:                   6. GENDER: 
    7. DATE :          8. INFORMANT  9. CONTACT NO 
    10. DATE OF ENROLLMENT  11. DATE OF COMPLETION 
      
S. 
NO 
CLINICAL 
FEATURES 
(SIGNS AND 
SYMPTOMS) 
BEFORE 
THE 
TREATMEN
T 
(0 th day) 
DURING 
THE 
TREATMEN
T 
(8 th day) 
AFTER 
THE 
TREATME
NT 
(15th day) 
1.  COUGH    
2.  RHINNORRHOEA    
3.  INTERMITTENT 
FEVER  
  
4.  HEADACHE    
5.  RUMBLING NOISE IN 
ABDOMEN  
  
6.  DIARRHOEA    
7.  MALAISE/ FATIGUE    
               
 
 
Date:       Signature of Principal Investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
 
POST GRADUATE DEPARTMENT OF KUZHANDHAI 
MARUTHUVAM 
A STUDY ON NEER KANAMAANTHAM 
DRUG COMPLIANCE 
 1. S. l. No:    2. OP/ IP No:                3. Name:                          
 4. Age:      5. Gender:   6. Date of Enrollment: 
 7. Date of completion:  8. Informant:    9. Reliablity:   
 
NAME OF THE DRUG   :  Athimathura chooranam 
FORM OF THE DRUG   :  Powder 
ADMINISTRATION & ADJUVANT :  Oral ,honey 
DOSE & DURATION   :        750mg-1. 5 gm Twice Daily for 7 Days  
 NO. OF DRUG PACKETS GIVEN : 
 NO. OF DRUG PACKETS RETURNED:  
 
  
Date:            Signature of Principal Investigator 
Day Date of Drug Intake Morning Evening 
Day 1    
Day2    
Day 3    
Day 4    
Day 5    
Day 6    
Day 7    
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
POST GRADUATE DEPARTMENT OF KUZHANDHAI 
MARUTHUVAM 
 
A STUDY ON NEERKANAMAANTHAM [COMMON COLD] IN CHILDREN 
           
WITHDRAWAL FORM 
 
  1. OP/ IP No:                          2. BED No:               3. Sl. No:  
    4.  NAME:                             5. AGE:                 6. GENDER:  
   7. DATE :               8. INFORMANT:  9. CONTACT NO: 
   10. DATE OF ENROLLMENT : 11. DATE OF COMPLETION: 
WITHDRAWAL  
 
Date of trial commencement    : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal   : Yes/ No  
Long absence at reporting   : Yes/ No 
Irregular treatment     : Yes/ No 
Shift of locality     : Yes/ No 
Complication adverse reactions if any : Yes/ No 
Exacerbation of symptoms   : Yes/ No 
 Pt not willing to continue   : Yes/ No 
 
 
Signature of Principal Investigator    Signature of parents/guardian 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
 
POST GRADUATE DEPARTMENT OF KUZHANDHAI 
MARUTHUVAM 
 
A STUDY ON ‘NEER KANAMAANTHAM’ 
ADVERSE REACTION FORM 
 
 1. S. l. No:    2. OP/ IP No:               3. Name:                          
  4. Age:   5. Gender:   6. Date of Enrollment: 
  7. Date of completion : 8. Informant:    9. Reliablity:   
 
    Name     : 
    Age      : 
    Gender    : 
    OPD/ IPD No    : 
    Registration No   : 
    Date of trial commencement  : 
    Date of withdrawal from trial  : 
    Description of adverse reaction : 
 
 
 
 
Date:      Signature of Principal Investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047.  
 
POST GRADUATE DEPARTMENT OF KUZHANDHAI 
MARUTHUVAM 
 
A STUDY ON ‘NEER KANAMAANTHAM’ 
    DIET FORM  
 
  1. S. l. No:    2. OP/ IP No:                3. Name:                          
  4. Age:   5. Gender:    6. Date of Enrollment: 
  7. Date of completion: 8. Informant:     9. Reliablity:   
 
¯½× Àò¾¢Â Ó¨È¸û 
§º÷ì¸ §ÅñÊÂ¨Å: 
 Ð º¢ Ãºõ, àÐÅ¨ ò Ð¨ÅÂø , §¸¡Ð¨Á ¸ïº¢ 
§º÷ì¸×õ.  
 Á½ò¾ì¸¡ ¢ì¸£¨Ã, ÅøÄ¡¨Ãì¸£¨Ã, º¢Ú¸£¨Ã, Ó¨ ì¸£¨Ã,  
  ÓÍÓÍì¨¸ §º÷ì¸×õ 
 Íñ¨¼ì¸¡ö, Å¡¨Æôâ, «Å¨ÃôÀ¢ïÍ §º÷ì¸×õ.  
 ¦Åû ¡ðÎì¸È¢ Ýô, ¿ñÎ Ãºõ «Õó¾×õ.  
    
   ¾Å¢÷ì¸ §ÅñÊÂ¨Å: 
 Ì ¢÷ À¡Éí¸û, É¢ôÒ Å¨¸¸û, ³Š¸¢Ã£õ ¾Å¢÷ì¸×õ.  
 Ì ¢÷ó¾ ¾¨ÃÂ¢ø ÁüÚõ Á¢ýÅ¢º¢È¢ìÌ §¿Ã¡¸ ¯ÈíÌÅ¨¾ò 
¾Å¢÷ì¸×õ.  
 Í¨Ãì¸¡ö, Ò¼Äí¸¡ö, À£÷ì¸í¸¡ö ¾Å¢÷ì¸×õ.  
 Á¡Ð¨ , ¾¢Ã¡ð¨º ¾Å¢÷ì¸×õ.  
 Ò¨¸, àº¢, ÀÉ¢¸¡üÈ¢ø ¿¼Á¡ÎÅ¨¾ò ¾Å¢÷ì¸×õ.  
 
Date:      Signature of Principal Investigator 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É-47.  
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È.  
ÀÊÅõ : II 
¿£÷¸½Á¡ó¾õ §¿¡öìÌ («¾¢ÁÐÃÝÃ½õ) ÀÃ¢¸Ã¢ôÒò¾¢È¨Éì ¸ñ¼È¢Ôõ 
ÁÕòÐÅ ¬ö×.  
´ôÒ¾ø ÀÊÅõ 
¬öÅ¡ Ã¡ø º¡ýÈ ¢ì¸Àð¼Ð 
¿¡ý ó¾ ÁÕòÐÅ ¬ö¨Å ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ Ôõ 
§¿¡Â¡ ¢Â¢ý ¦Àü§È¡ÕìÌ ÒÃ¢Ôõ Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ 
« ¢ì¸¢§Èý.  
§¾¾¢:        ¨¸¦Â¡ôÀõ: 
¼õ:        ¦ÀÂ÷: 
 
§¿¡Â ¢Â¢ý ¦Àü§È¡÷ ´ôÒ¾ø ÀÊÅõ 
 
 ±ýÉ¢¼õ ó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ 
ÁÕòÐÅ ÅÆ¢Ó¨Èô ÀüÈ¢Ôõ, ó¾ ÁÕòÐÅò¨¾ ¦¾¡¼÷óÐ ±ÉÐ ÌÆó¨¾Â¢ý 
¯¼ø Âì¸ò¨¾ì ¸ñ¸¡½¢ì¸×õ, «¾¨Éô À¡Ð¸¡ì¸ ÀÂýÀÎõ ÁÕòÐÅ 
¬ö×ìÜ¼ô ÀÃ¢§º¡¾¨É¸û ÀüÈ¢Ôõ ¾¢Õô¾¢ « ¢ìÌõ Å¨¸Â¢ø ¬ö× 
ÁÕòÐÅÃ¡ø Å¢ ì¸¢ì ÜÈôÀð¼Ð.  
 ¿¡ý ó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø ±ô§À¡Ð 
§ÅñÎÁ¡É¡Öõ ±ý ÌÆó¨¾¨Â Å¢ÎÅ¢òÐì¦¸¡ûÙõ ¯Ã¢¨Á¨Â 
¦¾Ã¢ó¾¢Õì¸¢§Èý.  
¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì ¦¸¡ñÎ 
(«¾¢ÁÐÃÝÃ½õ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬ö×ìÌ ±ÉÐ 
ÌÆó¨¾¨Â ¯ðÀÎò¾ ´ôÒ¾ø « ¢ì¸¢§Èý.  
 
                  ¦Àü§È¡÷ ¦ÀÂ÷  
    ¨¸¦Â¡ôÀõ: 
    º¡ðº¢ì¸¡Ã÷ ¦ÀÂ÷: 
      ¨¸¦Â¡ôÀõ          
 
§¾¾¢: 
 
¼õ: 
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¾¸Åø ÀÊÅõ 
    ¿£÷¸½Á¡ó¾õ §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸ ¢ý («¾¢ÁÐÃÝÃ½õ) ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ.  
Ó¾ý¨Á ¬Ã¡öîº¢Â¡ ÷ ¦ÀÂ÷ :  Dr. K. À¢Ã¢ò¾¡ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷               : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                              ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ, ¦ºý¨É-47.  
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý 
¿£÷¸½Á¡ó¾õ ±ýÛõ §¿¡Â¢ø ÁÕòÐÅ ¬Ã¡öîº¢Â¢ø ®ÎÀðÎû§ ý.  
¿£÷¸½Á¡ó¾õ ±ýÛõ º¢ò¾ ÁÕòÐÅò¾¢ø ¦º¡øÄôÀÎõ §¿¡Â¡ÉÐ ÕÁø, 
ãì¸¢ø ¿£÷ÅÊ¾ø,Å¢ðÎ Å¢ðÎ ÍÃõ ÅÕ¾ø,ÅÂ¢Ú ¦À¡ÕÓ¾ø,ÀÄÅ¢¾Á¡É §À¾¢ 
Ó¾Ä¢Â ÌÈ¢Ì½í¸û ¸¡½ôÀÎõ ¾ý¨ÁÔ¨¼ÂÐ.  
ó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨  §¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ 
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸ Ð ÌÆó¨¾¨Â ¯ðÀÎò¾×õ ¯û§ ý.  
Ð ºõÀó¾Á¡É ¾í¸ Ð ÌÆó¨¾Â¢ý «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ 
¨Åì¸ôÀÎõ ±É ¯Ú¾¢ « ¢ì¸¢§Èý. ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ 
¦¾¡¨¸Ôõ ÅÆí¸ôÀ¼ Á¡ð¼¡Ð.  
ó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¾í¸ Ð ÌÆó¨¾Â¢ý ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ                         
²üÀÎõ Àðºò¾¢ø §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ º¢¸¢î¨º « ¢ì¸ôÀÎõ.  
ó¾ ¬Ã¡öîº¢ìÌ ¾í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ÌÆó¨¾¨Â ¯ðÀÎòÐõ                       
Àðºò¾¢ø, ¯ûÁÕó¾¡¸ («¾¢ÁÐÃÝÃ½õ) Õ §Å¨  (750Á¢¸¢-1Á¢¸¢) ¸¡¨Ä,Á¡¨Ä 
7 ¿¡ð¸û «øÄÐ «¾üÌ §ÁÖõ º¢Ä ¾¢Éí¸ÙìÌ ¯ð¦¸¡û  §ÅñÎõ.  
ó¾ ¬Ã¡öîº¢Â¢ø §¿¡Â¢ÉÃ¡¸ §º÷ó¾ À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ 
ø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ ¾í¸ Ð ÌÆó¨¾¨Â Å¢Äì¸¢ì 
¦¸¡û Ä¡õ.  
ó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ ÁüÈ Å¢ÀÃí¸ÙìÌõ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ 
«È¢Å¾üÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ Ã¡É Dr. K. À¢Ã¢ò¾¡ (Àð¼ §ÁüÀÊôÀ¡ ÷, 
ÌÆó¨¾ ÁÕòÐÅ À¢Ã¢×). ¨¸ô§Àº¢ ±ñ: 9994545800 ±ô§À¡Ðõ ¦¾¡¼÷Ò 
¦¸¡û Ä¡õ.  
§ÁÖõ ó¾ ¬Ã¡öîº¢ìÌ IEC (¿¢ÚÅÉ ¿£¾¢¦¿È¢ìÌØ) º¡ýÚ ¦ÀÈôÀðÎû Ð 
ó¾ ÁÕóÐ º¢ÈôÀ¡¸ ¿£÷¸½Á¡ó¾õ §¿¡öì¸¡¸ «í¸£¸Ã¢ôÀð¼ º¢ò¾ 
ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎû Ð. ²ü¸É§Å ¯À§Â¡¸ò¾¢ø ¯û Ð §À¡ýÈ ÁÕóÐ 
ÐÅ¨Ã §¿¡Â¡ ¢¸ ¢¼õ ±ó¾ Å¢¾ Àì¸ Å¢¨ ×¸¨  ²üÀÎò¾Å¢ø¨Ä.  
§ÁÖõ ¯½× Ó¨ÈÂ¢ø Àò¾¢Âõ ¸¡ìÌÁ¡Ú «È¢×Úò¾ ÀÎ¸¢ÈÐ.  
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